Document:

Exhibit 10.21

 

CONFIDENTIAL
PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
FOR SUCH PORTIONS. ASTERISKS DENOTE OMISSIONS.

 

EXCLUSIVE PATENT LICENSE AND RESEARCH

COLLABORATION
AGREEMENT

 

by and between

 

Cue
Biopharma, Inc.

 

and

 

MERCK SHARP & DOHME CORP.

 

    	 	1	 

     

    

 

EXCLUSIVE PATENT LICENSE AND RESEARCH COLLABORATION
AGREEMENT

 

This Agreement
( “Agreement”) is effective as of November 14, 2017, (the “Effective
Date”) and is entered into by and between CUE BIOPHARMA, INC., a corporation organized and existing under the laws of
Delaware (“Company”) and MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws
of New Jersey (“Merck”).

 

RECITALS:

 

WHEREAS, Company has developed Company
Know-How (as hereinafter defined) and has rights to Company Patent Rights (as hereinafter defined) related to antigen-specific
T cell-targeted biologics, including an exclusive license to certain intellectual property rights pursuant to an Amended and Restated
License Agreement dated July 31, 2017 between Company and Albert Einstein College of Medicine, Inc. (“Albert Einstein”),
a corporation organized and existing under the laws of the State of New York, having an office and place of business at 1300 Morris
Park Avenue, Bronx, New York 10461 as successor-in-interest to Albert Einstein College of Medicine of Yeshiva University, a Division
of Yeshiva University (the “Amended and Restated Einstein License Agreement”);

 

WHEREAS, such antigen-specific T cell-targeted
biologics have multiple potential uses, including but not limited to the treatment of Autoimmune Disease (as hereinafter defined),
cancer, and infectious diseases;

 

WHEREAS, Merck and Company desire to
enter into a research collaboration to research and develop certain antigen-specific T cell-targeted biologics and in particular
Cue Biologics, Compounds and Products of potential utility for treating Initial Indications in Autoimmune Disease (as those terms
are hereinafter defined) upon the terms and conditions set forth herein, with the goal of identifying and/or optimizing novel biologics
to be developed and commercialized by Merck;

 

WHEREAS, Merck desires to obtain a license
under the Company Patent Rights and Company Know-How upon the terms and conditions set forth herein, and Company desires to grant
such a license;

 

NOW, THEREFORE, in consideration of
the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged,
Company and Merck hereby agree as follows:

 

Article
1  DEFINITIONS.

 

Unless specifically set forth to the contrary herein, the following
terms, whether used in the singular or plural, shall have the respective meanings set forth below.

 

		1.1	“AAALAC” shall mean the Association for Assessment
and Accreditation of Laboratory Animal Care International.

 

		1.2	“Act” shall mean, as applicable, the United States
Federal Food, Drug and Cosmetic Act, 21 U.S.C. §§ 301 et seq., and/or the Public Health Service Act, 42 U.S.C. §§
262 et seq., as amended from time to time.

 

    	 	2	 

     

    

 

		1.3	“Affiliate” shall mean: (i) any corporation or business
entity of which, now or hereafter, fifty percent (50%) or more of the securities or other ownership interests representing the
equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by Merck or Company;
or (ii) any corporation or business entity which, now or hereafter, directly or indirectly, owns, controls or holds fifty percent
(50%) (or the maximum ownership interest permitted by law) or more of the securities or other ownership interests representing
the equity, the voting stock or, if applicable, the general partnership interest, of Merck or Company; or (iii) any corporation
or business entity of which, now or hereafter, fifty percent (50%) or more of the securities or other ownership interests representing
the equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by a corporation
or business entity described in (i) or (ii).

 

		1.4	“Agreement” shall have the meaning given such term
in the preamble to this document.

 

		1.5	“Antigen” as used herein shall mean any protein or
Peptide that, when bound or presented by a Disease-Associated Allele, binds to T cells or evokes an immune response. 

 

		1.6	“Applicable Laws” means any and all applicable laws
of any jurisdiction which are applicable to any of the Parties or their respective Affiliates in carrying out activities hereunder
or to which any of the Parties or their respective Affiliates in carrying out the activities hereunder is subject, and shall include
all statutes, enactments, acts of legislature, laws, ordinances, rules, regulations, notifications, guidelines, policies, directions,
directives and orders of any statutory authority, tribunal, board, or court or any central or state government or local authority
or other governmental entity in such jurisdictions, including the Act, GLPs, GCPs and GMPs.

 

		1.7	“Autoimmune Disease” means a disease or inflammatory
disorder in which the body’s immune system produces antibodies and/or pro-inflammatory chemical agents that attack its own
tissues, leading to the deterioration and in some cases to the destruction of such tissue.

 

		1.8	“Calendar Quarter” shall
mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31.

 

		1.9	“Calendar Year” shall mean each successive period
of twelve (12) months commencing on January 1 and ending on December 31.

 

		1.10	“Change of Control” shall mean with respect to a
Party: (1) the sale of all or substantially all of such Party’s assets or business relating to this Agreement; (2) a merger,
reorganization or consolidation involving such Party in which the voting securities of such Party outstanding immediately prior
thereto cease to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after
such merger, reorganization or consolidation; or (3) a person or entity, or group of persons or entities, acting in concert acquire
at least fifty percent (50%) of the voting equity securities or management control of such Party. 

 

		1.11	“Clinical Trial” shall mean a Phase I Clinical Trial,
Phase II Clinical Trial, Phase III Clinical Trial, and/or Post-Approval Clinical Trial. 

 

		1.12	“Combination Product” shall mean a Product that includes one or more active
pharmaceutical ingredients other than Compound in combination with Compound. All references to Product in this Agreement shall
be deemed to include Combination Product.

 

    	 	3	 

     

    

 

		1.13	“Commercially Reasonable Efforts” shall mean, with respect to the efforts to
be expended by a Party with respect to any objective, such reasonable and diligent, good faith efforts to accomplish such objective
as such Party would normally use to accomplish a similar objective under similar circumstances. It is understood and agreed that
with respect to the Research, Development and Commercialization of Product by either Party, such efforts shall be substantially
equivalent to those efforts and resources commonly used by such Party for biological products owned by it or to which it has rights,
which product is at a similar stage in its Development or product life and is of similar market potential taking into account efficacy,
safety, approved labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position
of the product, the likelihood of regulatory approval given the Regulatory Authority involved, the profitability of the product
including the amounts payable to licensors of patent or other intellectual property rights, alternative products, other risks associated
with the Development or Commercialization of the product and other relevant factors. Commercially Reasonable Efforts shall be determined
on a market-by-market and Indication-by-Indication basis for a particular Product, and it is anticipated that the level of effort
will be different for different markets, and will change over time, reflecting among other things changes in the status of the
Product and the market(s) involved.

 

		1.14	“Commercialization” shall mean any and all activities
related to the import, export, transportation, storage, marketing, detailing, promotion, distribution, sale or other disposition
and/or other approved use of a Product in a country or region in the Territory, including: (a) strategic marketing, sales force
detailing, advertising, medical affairs, reimbursement and market access activities and market and product support; and (b) all
customer support, distribution matters, invoicing and sales activities. When used as a verb, “to Commercialize” and
“Commercializing” means to engage in Commercialization, and “Commercialized” has a corresponding meaning.
For clarity, Commercialization excludes any Research, Development or Manufacturing activities.

 

		1.15	“Company” shall have the meaning given such term
in the preamble to this Agreement.

 

		1.16	“Company Information and Inventions” shall mean all
protocols, formulas, data, Inventions, know-how and trade secrets, patentable or otherwise, resulting from the Research Program
developed or invented solely by employee(s) of Company and/or its Affiliates, and/or a Third Party acting on behalf of Company
and/or its Affiliates, and not employed by Merck and/or its Affiliates.

 

		1.17	“Company Know-How” shall mean all information and
materials, including but not limited to discoveries, improvements, processes, methods, protocols, formulas, data, inventions (including
without limitation Company Information and Inventions and Company’s rights in Joint Information and Inventions), know-how
and trade secrets, patentable or otherwise, which during the term of this Agreement: (i) are Controlled by Company or its Affiliates;
(ii) are not generally known; and (iii) are necessary or useful to Merck in the Field, or necessary or useful to Merck in connection
with the Research Program and the Research, Development, Manufacture, Commercialization or use of Compound or Product in the Territory;
excluding, however, any Merck Know-How. Company Know-How includes Einstein Know-How and Cue Know-How. 

 

		1.18	“Company Patent Rights” shall mean Patent Rights
that during the term of this Agreement are Controlled by Company or any of its Affiliates, including, but not limited to, those
listed on Schedule 1.1, which: (i) claim or cover a Cue Biologic, Compound and/or Product, or a method of use or process
of Manufacture thereof, including without limitation any improvements; or (ii) claim or cover Company Information and Inventions.
Company Patent Rights include Einstein Patent Rights and Cue Patent Rights. 

 

    	 	4	 

     

    

 

		1.19	“Competing Pharma” shall mean a company or group
of companies acting in concert (a) for which the collective worldwide sales of ethical pharmaceutical products in the preceding
Calendar Year were one billion United States dollars (US$1,000,000,000) or more, or (b) which has a research, development or commercialization
program for any preparation or product that may be used for the treatment of an Initial Indication, or any other preparation or
product that is reasonably considered to be competitive with any Cue Biologic, Compound or Product.

 

		1.20	“Competing Pharma Change of Control” shall mean a
Change of Control in which a company or group of companies acting in concert (a) for which the collective worldwide sales of ethical
pharmaceutical products in the Calendar Year that preceded the Change of Control were one billion United States dollars (US$1,000,000,000)
or more, or (b) which has a research, development or commercialization program for any preparation or product that may be used
for the treatment of an Initial Indication, or any other preparation or product that is reasonably considered to be competitive
with any Cue Biologic, Compound or Product, is the acquirer (by asset purchase, merger, consolidation, reorganization or otherwise)
as part of such Change of Control.

 

		1.21	“Compound” shall mean a Product Candidate; or a derivative thereof [***].

 

		1.22	“Control”,
“Controls” or “Controlled by” shall
mean with respect to any item of or right under Company Patent Rights, Company Know-How, Merck Patent Rights, Merck Know-How, or
Joint Patent Rights, or other intellectual property assets or rights, as applicable, the possession of (whether by ownership or
license, other than pursuant to this Agreement) or the ability of a Party to grant access to, or a license or sublicense of, such
items or right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party existing
at the time or in effect during the time such Party would be required hereunder to grant the other Party such access or license
or sublicense.

 

		1.23	“Cue Biologic” shall mean [***].

 

		1.24	“Cue Biologics Patent Rights” shall be as defined
in Section 7.1.1. 

 

		1.25	“Cue Biologics-Specific Information and Inventions” shall
be as defined in Section 7.1.1. 

 

		1.26	“Cue Know-How” shall man all Company Know-How other
than Einstein Know-How.

 

		1.27	“Cue Patent Rights” shall mean all Company Patent
Rights other than Einstein Patent Rights.

 

		1.28	“Cue Platform”
shall mean Company’s proprietary Antigen-specific T cell-targeted biologic platform that produces biologics designed and
engineered to selectively modulate function of T cell subsets. 

 

		1.29	“Cue Platform Biologic” shall mean [***].

 

		1.30	“Development” means any and all clinical drug development
activities, Clinical Trials, statistical analysis and report writing, the preparation and submission of regulatory filings, regulatory
affairs with respect to the foregoing and all other activities necessary or reasonably useful or otherwise requested or required
by a Regulatory Authority as a condition or in support of obtaining or maintaining a regulatory approval for a Cue Biologic, Compound
or Product, and “Develop”, “Developed” and “Developing” will have corresponding meanings. For
clarity, Development excludes any Research, Commercialization or Manufacturing activities. 

 

    	 	5	 

     

    

 

		1.31	“Disease-Associated Allele” shall mean any allele
from any species which is associated with [***]. 

 

		1.32	“Einstein Know-How” shall mean all know-how licensed
to Company under the Amended and Restated Einstein License Agreement.

 

		1.33	“Einstein Patent Rights” shall mean all patent rights
licensed to Company under the Amended and Restated Einstein License Agreement.

 

		1.34	“Exclusions Lists” shall be as defined in Section
1.90 Violation. 

 

		1.35	“Field” shall mean [***].

 

		1.36	[***]. 

 

		1.37	“First Commercial Sale” shall mean, with respect
to any Product, the first sale for end use or consumption of such Product in a country, excluding, however, any sale or other distribution
for use in a Clinical Trial.

 

		1.38	“Good Clinical Practices” or “GCPs”
shall mean the applicable then-current Good Clinical Practices as such term or its equivalent
is defined from time to time by the United States Food and Drug Administration or other relevant Regulatory Authority having jurisdiction
over the Development, Manufacture or Commercialization of Product in the Territory pursuant to its regulations, guidelines or otherwise,
as applicable.

 

		1.39	“Good Laboratory Practices” or “GLPs”
shall mean the applicable then-current standards for laboratory activities for pharmaceuticals
or biologicals, as set forth in the Act and any regulations or guidance documents promulgated thereunder, as amended from time
to time, together with any similar standards of good laboratory practice as are required by any Regulatory Authority in the Territory.

 

		1.40	“Good Manufacturing Practices” or “GMPs”
shall mean the applicable then-current Good Manufacturing Practices as such term or its equivalent
is defined from time to time by the United States Food and Drug Administration or other relevant Regulatory Authority having jurisdiction
over the Development, Manufacture or Commercialization of Product in the Territory pursuant to its regulations, guidelines or otherwise,
as applicable.

 

		1.41	“Human Leukocyte Antigen” or “HLA”
shall mean a protein or protein complex involved in the presentation of Peptide antigens to T
cells. 

 

		1.42	[****]

 

		1.43	“IND” shall mean an investigational new drug application,
clinical study application, clinical trial exemption, or similar application or submission for approval to conduct human clinical
investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority.

 

    	 	6	 

     

    

 

		1.44	“IND Enabling Studies” shall mean the genotoxicity,
acute toxicology, safety, pharmacology, and/or sub-chronic toxicology studies in species using applicable GLPs that in Merck’s
sole discretion satisfy applicable regulatory requirements and meet the standard necessary for submission as part of an IND filing
with a Regulatory Authority. 

 

		1.45	“Indication” shall mean a separate and distinct disease
or medical condition in humans which a Product that is in Clinical Trials is intended to treat, prevent and/or diagnose and/or
for which a Product has received Marketing Authorization.

 

		1.46	“Indication Specific Peptide” shall mean a Peptide
Researched or Developed pursuant to the Research Program which is [***]. 

 

		1.47	“Initial Indication” shall mean [***]
and “Initial Indications” shall mean [***],
collectively. 

 

		1.48	“Information” shall mean any and all information
and data, including without limitation all Merck Know-How, all Company Know-How, and all other scientific, pre-clinical, clinical,
regulatory, manufacturing, marketing, financial and commercial information or data, whether communicated in writing or orally or
by any other method, which is provided by one Party to the other Party in connection with this Agreement.

 

		1.49	“Invention”
shall mean any process, method, composition of matter, article of manufacture, discovery or finding
that is conceived and/or reduced to practice as a result of the Research Program. 

 

		1.50	“Joint Information and Inventions” shall mean all
protocols, formulas, data, Inventions, know-how and trade secrets, patentable or otherwise, resulting from the Research Program
and developed or invented jointly by employee(s) of Merck and/or its Affiliates, and/or a Third Party acting on behalf of Merck
and/or its Affiliates, on the one hand, and by employee(s) of Company and/or its Affiliates, and/or a Third Party acting on behalf
of Company and/or its Affiliates, on the other hand.

 

		1.51	“Joint Patent Rights” shall mean Patent Rights that
claim or cover Joint Information and Inventions. 

 

		1.52	“Joint Steering Committee”
shall mean the joint steering committee established to facilitate the Research Program as more
fully described in Section 2.4.

 

		1.53	“Maintained Initial Indication”
shall mean an Initial Indication in which Merck has not discontinued Research, Development and Commercialization efforts with respect
to any Compound or Product pursuant to Section 2.11.5. 

 

		1.54	“Major Market” shall mean [***].

 

		1.55	“Manufacturing” means the production, manufacture,
synthesis, processing, filling, formulating, finishing, packaging, labeling, shipping and holding of Cue Biologic, Compound or
Product or any intermediate thereof, including sequencing, process development, process qualification and validation, scale-up,
commercial manufacture and analytic development, product characterization, stability testing, quality assurance and quality control.
“Manufacturing” refers to both pre-clinical and clinical Manufacturing for Research and Development, and Manufacturing
for Commercialization. “Manufacture” and “Manufactured” will have corresponding meanings. For clarity,
“Manufacturing” excludes Research, Development or Commercialization activities. 

 

    	 	7	 

     

    

 

		1.56	“Marketing Authorization” shall mean all approvals
from the relevant Regulatory Authority necessary to market and sell a Product in the applicable country (including without limitation,
in countries outside of the United States, all applicable pricing and governmental reimbursement approvals only if required to
market and sell Product in a country).

 

		1.57	“Merck” shall have the meaning given such term in
the preamble to this Agreement.

 

		1.58	“Merck Information and Inventions” shall mean all
protocols, formulas, data, Inventions, know-how and trade secrets, patentable or otherwise, resulting from the Research Program
developed or invented solely by employee(s) of Merck and/or its Affiliates, and/or a Third Party acting on behalf of Merck and/or
its Affiliates, and not employed by Company and/or its Affiliates.

 

		1.59	“Merck Know-How” shall mean all information and materials,
including but not limited to discoveries, improvements, processes, methods, protocols, formulas, data, inventions (including without
limitation Merck Information and Inventions and Merck’s rights in Joint Information and Inventions), know-how and trade secrets,
patentable or otherwise, which during the term of this Agreement: (i) are Controlled by Merck; (ii) are not generally known; and
(iii) are in Merck’s opinion necessary to Company in the performance of its obligations under the Research Program.

 

		1.60	“Merck Patent Rights” shall mean Patent Rights that
during the term of this Agreement are Controlled by Merck or any of its Affiliates, or to which Merck or any of its Affiliates,
through license or otherwise, acquires rights, which: (i) claim or cover Compound and/or Product; or (ii) claim or cover Merck
Information and Inventions. 

 

		1.61	“NDA” shall mean a new drug application, biologics
license application, Marketing Authorization application, filing pursuant to Section 510(k) of the Act, or similar application
or submission for Marketing Authorization of a Product filed with a Regulatory Authority to obtain marketing approval for a biological,
pharmaceutical or diagnostic product in that country or in that group of countries.

 

		1.62	“Net Sales” shall mean the gross invoice price (not
including value added taxes, sales taxes, or similar taxes) of Product sold by Merck or its Related Parties to the first Third
Party after deducting, if not previously deducted, from the amount invoiced or received:

 

		1.62.1	trade and quantity discounts, other than early payment cash discounts;

 

		1.62.2	returns, rebates, chargebacks and other allowances;

 

		1.62.3	retroactive price reductions that are actually allowed or granted;

 

		1.62.4	deductions for Health Care Reform fees and similar deductions to gross invoice price of Product
imposed by Regulatory Authorities or other governmental entities;

 

    	 	8	 

     

    

 

		1.62.5	a fixed amount equal to [***] of the amount invoiced to cover bad debt, early payment cash discounts,
transportation and insurance and custom duties; and

 

		1.62.6	the standard inventory cost of devices or delivery systems used for dispensing or administering
Product.

 

[***]

 

With respect to sales of Combination
Products, Net Sales shall be calculated on the basis of the gross invoice price of Product(s) containing the same strength of Compound
sold without other active ingredients. In the event that Product is sold only as a Combination Product, Net Sales shall be calculated
on the basis of the gross invoice price of the Combination Product multiplied by a fraction, the numerator of which shall be the
inventory cost of Compound in the Product and the denominator of which shall be the inventory cost of all of the active ingredients
in the Combination Product. Inventory cost shall be determined in accordance with Merck's regular accounting methods, consistently
applied. The deductions set forth in Section 1.62.1 through Section 1.62.6 will be applied in calculating Net Sales
for a Combination Product. In the event that Product is sold only as a Combination Product and either Party reasonably believes
that the calculation set forth in this Paragraph does not fairly reflect the value of Compound relative to the other active ingredients
in the Combination Product, the Parties shall reasonably negotiate, in good faith, other means of calculating Net Sales with respect
to Combination Products.

 

		1.63	“Party” shall
mean Merck or Company, individually, and “Parties” shall mean Merck and Company, collectively.

 

		1.64	“Patent Rights” shall mean any and all patents and
patent applications in the Territory (which for the purpose of this Agreement shall be deemed to include certificates of invention
and applications for certificates of invention), including divisionals, continuations, continuations-in-part, reissues, renewals,
substitutions, registrations, re-examinations, revalidations, extensions, supplementary protection certificates, pediatric exclusivity
periods and the like of any such patents and patent applications, and foreign equivalents of the foregoing.

 

		1.65	“Peptide” shall mean a series of two or more amino
acids connected by peptide bonds. 

 

		1.66	“Person” means any individual, partnership, joint
venture, limited liability company, corporation, firm, trust, association, unincorporated organization, governmental authority
or agency, or any other entity not specifically listed herein.

 

		1.67	“Phase I Clinical Trial” shall mean a human clinical
trial in any country that would satisfy the requirements of 21 CFR 312.21(a).

 

		1.68	“Phase II Clinical Trial” shall mean a human clinical
trial in any country that would satisfy the requirements of 21 CFR 312.21(b).

 

		1.69	“Phase III Clinical Trial” shall mean a human clinical
trial in any country that would satisfy the requirements of 21 CFR 312.21(c).

 

		1.70	“Platform Information and Inventions” shall be as
defined in Section 7.1.2. 

 

		1.71	“Platform Patent Rights” shall be as defined in Section
7.1.2. 

 

    	 	9	 

     

    

 

		1.72	“Post-Approval Clinical Trial” shall mean any clinical
trial conducted in an Indication after the Regulatory Approval of such Indication. 

 

		1.73	“Product(s)” shall mean any pharmaceutical or biological
preparation in final form containing a Compound: (i) for sale by prescription, over-the-counter or any other method; or (ii) for
administration to human patients in a Clinical Trial, for any and all uses in the Field, including without limitation any Combination
Product.

 

		1.74	“Product Candidate” shall mean a Cue Biologic which:
(i) meets or exceed Proof of Concept, as determined by Merck in accordance with its usual procedures for the development of new
biological entities; and (ii) is designated in writing pursuant to Section 2.2.4 as a Product Candidate by Merck to Company.

 

		1.75	“Proof of Concept” shall mean the demonstration of
all or substantially all of the properties outlined in the Product Candidate Profile as defined in Schedule 2.1 Research
Program, as determined by Merck in its sole discretion.

 

		1.76	“Proof of Mechanism” shall mean the demonstration
of biologically significant effect of a Cue Biologic [***], as determined by the Joint
Steering Committee pursuant to Section 2.2.2.

 

		1.77	“Proposed Product Candidate”
shall be a Cue Biologic which has achieved Proof of Mechanism as determined by the Joint Steering Committee, as reflected in meeting
minutes of the Joint Steering Committee.

 

		1.78	“Qualifying Phase II Clinical Trial” shall mean a
human clinical trial, in any country, the principal purpose of which is a confirmation of efficacy and safety, consistent with
that observed in previous Clinical Trial(s) of the relevant Product, in the target population, at the intended clinical dose or
doses or range of doses, on a sufficient number of subjects and for a sufficient period of time to determine the optimal manner
of use of the Product (dose and dose regimen) prior to the Initiation of a Phase III Clinical Trial of such Product. For clarity,
the Parties’ expectation is that a Qualifying Phase II Clinical Trial will be a phase IIb Clinical Trial which is intended
to confirm the efficacy demonstrated in a prior phase IIa Clinical Trial or phase Ib Clinical Trial. 

 

		1.79	“Regulatory Authority” shall mean any applicable
government regulatory authority involved in granting approvals for the manufacturing, marketing, reimbursement and/or pricing of
a Product in the Territory, including, in the United States, the United States Food and Drug Administration and any successor governmental
authority having substantially the same function.

 

		1.80	“Regulatory T cells” or “T-regs” also
known as suppressor T cells, are a subpopulation of T cells which modulate the immune system, maintain tolerance to self-antigens,
and prevent autoimmune disease.

 

		1.81	“Related Party” shall mean each of Merck, its Affiliates,
and their respective sublicensees (which term does not include distributors), as applicable. 

 

		1.82	“Research” means activities related to the design,
discovery, identification, synthesis, research, pre-clinical development, preclinical toxicology studies, profiling, characterization,
improvement or optimization of a Cue Biologic, Compound or Product. For clarity, “Research” excludes Development, Commercialization
or Manufacturing activities.

 

    	 	10	 

     

    

 

		1.83	“Research Program” shall mean the Research activities
undertaken by the Parties as set forth in Article 2 and Schedule 2.1, as may be revised from time to time pursuant
to Section 2.1, Section 2.2, or Section 2.10.

 

		1.84	“Research Program Term” shall mean the duration of
the Research Program as it may be extended or terminated as described more fully in Section 2.10 and Article 8.

 

		1.85	“Royalty Period” shall be as defined in Section
5.4.1(c).

 

		1.86	“Term” is defined in Section 8.1.

 

		1.87	“Territory” shall mean all of the countries in the
world, and their territories and possessions.

 

		1.88	“Third Party” shall mean an entity other than Merck
and its Related Parties, and Company and its Affiliates. 

 

		1.89	“Valid Patent Claim” shall mean a claim of an issued,
unexpired and in-force patent included within the Company Patent Rights or Joint Patent Rights that claims a Compound as a composition
of matter, which claim has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency
of competent jurisdiction (which decision is not appealable or has not been appealed within the time allowed for appeal), and which
claim has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination, supplemental
examination or disclaimer or otherwise.

 

		1.90	“Violation”
                                         shall mean that either Company, or any of its officers
                                         or directors has been: (a) convicted of any of the felonies identified among the exclusion
                                         authorities listed on the U.S. Department of Health and Human Services, Office of Inspector
                                         General (OIG) website, including 42 U.S.C. 1320a-7(a) (https://oig.hhs.gov/exclusions/index.asp);
                                         and/or (b) identified in the OIG List of Excluded Individuals/Entities (LEIE) database
                                         (https://oig.hhs.gov/exclusions/exclusions_list.asp) or the U.S. General Services
                                         Administration's list of Parties Excluded from Federal Programs (https://www.sam.gov/portal/public/SAM/)
                                         (each of (a) and (b), singly and collectively, the “Exclusions Lists”).

 

    	 	11	 

     

    

 

Article
2  RESEARCH PROGRAM, GOVERNANCE, exclusive efforts

 

		2.1	General. Company and Merck shall engage in the Research Program
upon the terms and conditions set forth in this Agreement. The activities to be undertaken in the course of the Research Program
are set forth in Schedule 2.1 as may be revised from time to time upon mutual written agreement by authorized representative(s)
of the Parties.

 

		2.2	Conduct of Research. The Research Program is directed to: (i)
the Research by Company of Cue Biologics up to Proof of Mechanism for each of the Initial Indications; and, subject to Section
2.2.2; (ii) the further Research and/or Development by Merck of Proposed Product Candidates. Subject to Section 2.2.4,
Merck may, in its sole discretion, elect [****] Product Candidates for use by Merck and its Related Parties in efforts
to Research, Develop, Manufacture and Commercialize Compounds and Products.

 

		2.2.1	Until the expiration of the Research Program Term, Company and Merck each shall proceed diligently
with the work set out in the Research Program by using their respective reasonable good faith efforts to allocate sufficient time,
effort, equipment and facilities to the Research Program and to use personnel with sufficient skills and experience as are required
to accomplish the Research Program in accordance with the terms of this Agreement and Schedule 2.1 as may be revised from
time to time pursuant to Section 2.1.

 

		2.2.2	Upon the generation of data supporting achievement of Proof of Mechanism for each Cue Biologic,
Company shall present such information along with the identity of the Cue Biologic to the Joint Steering Committee. Following a
determination by the Joint Steering Committee that such Cue Biologic has achieved Proof of Mechanism as reflected in the meeting
minutes of the Joint Steering Committee, such Cue Biologic shall constitute a Proposed Product Candidate. Merck shall thereafter
perform the Research and/or Development activities assigned under the Research Program for the Proposed Product Candidate. Company
shall have responsibility for supply of such Proposed Product Candidate.

 

		2.2.3	Upon achievement of Proof of Concept for one or more Proposed Product Candidates, Merck shall provide
written notice to Company that such one or more Proposed Product Candidates have achieved Proof of Concept.

 

		2.2.4	Following written notice to Company of the achievement of Proof of Concept for a Proposed Product
Candidate, Merck shall conduct an internal review to determine in its sole discretion whether it wishes to elect the Proposed Product
Candidate as a Product Candidate. Merck shall then request through the Joint Steering Committee a meeting with Company to discuss
and mutually agree upon a technology transfer strategy to provide for the continued supply and Manufacturing of Product Candidates
for IND Enabling Studies. Following Merck’s request for a meeting pursuant to this Section 2.2.4 and mutual agreement
on the technology transfer strategy, Merck may elect in its sole discretion to designate a Proposed Product Candidate as a Product
Candidate and provide written notice to Company informing them of such election. Parties shall thereafter work to execute on the
mutually-agreed upon technology transfer strategy.

 

Merck shall be entitled
to utilize the services of its Affiliates and Third Parties to perform its Research Program activities, provided that all such
Affiliates and Third Parties are bound or agree to be bound by confidentiality and non-use obligations no less stringent than that
contained in this Agreement. Company shall be entitled to utilize the service of Third Parties to perform its Research Program
activities only upon Merck’s prior written consent or as specifically set forth in Schedule 2.1. Notwithstanding the
foregoing, each Party shall remain at all times fully liable for its respective responsibilities under the Research Program.

 

    	 	12	 

     

    

 

		2.3	Use of Research Funding. Company shall apply any Research funding
it receives from Merck under this Agreement solely to carry out its Research Program activities in accordance with Schedule
2.1, as may be revised from time to time pursuant to Section 2.1, and the terms and conditions of this Agreement. Apart
from the foregoing, each Party shall be responsible for its own cost and expense in carrying out its activities under the Research
Program.

 

		2.4	Joint Steering Committee. The Parties hereby establish a committee
to facilitate the Research Program as follows:

 

		2.4.1	Composition of the Joint Steering Committee. The Research Program shall be conducted under
the direction of a joint steering committee (the “Joint Steering
Committee”) comprised of two (2) Merck representatives (who shall be employees of Merck or its Affiliate, as applicable)
and two (2) Company representatives (who shall be employees of Company or its Affiliate, as applicable). Each Party may change
its representatives on the Joint Steering Committee from time to time in its sole discretion, effective upon notice to the other
Party of such change. These representatives shall have appropriate technical credentials, experience and knowledge, and ongoing
familiarity with the Research Program. Additional representative(s) or consultant(s) may from time to time, by mutual consent of
the Parties, be invited to attend Joint Steering Committee meetings, subject to such representative’s or consultant’s
written agreement to comply with the requirements of Section 4.1. The Joint Steering Committee shall be chaired by a representative
of Merck. The role of the chairperson shall be to preside in person or telephonically at meetings of the Joint Steering Committee,
to prepare and circulate agendas and to ensure the preparation of minutes. The chairperson of the Joint Steering Committee will
be responsible for preparing reasonably detailed written minutes of all Joint Steering Committee meetings that reflect, without
limitation, material decisions made at such meetings. The chairperson shall send draft meeting minutes to each member of the Joint
Steering Committee for review and approval reasonably promptly after each meeting. Such minutes will be deemed approved unless
one or more of the members of the Joint Steering Committee objects to the accuracy of such minutes within ten (10) business days
of receipt. Decisions of the Joint Steering Committee shall be made unanimously by the representatives. In the event that the Joint
Steering Committee cannot or does not, after reasonable good faith efforts, reach agreement on an issue, the resolution and/or
course of conduct shall be determined by Merck, in its sole discretion.

 

    	 	13	 

     

    

 

		2.4.2	Scope of Joint Steering Committee Oversight. The Joint Steering Committee shall be responsible
for overseeing the Research Program, including to: (i) review and amend the Research Program activities set forth in Schedule
2.1 as may be revised from time to time pursuant to Section 2.1; (ii) review and coordinate the Parties’ activities
under the Research Program; (iii) confer regarding the status of the Research Program and the progress under the Research Program
and to make determinations and decisions in connection with the activities under the Research Program (including issues of priority);
(iv) review relevant data under the Research Program; (v) consider and advise on any technical issues that arise under the Research
Program; (vi) review and advise on any budgetary and economic matters relating to the Research Program which may be referred to
the Joint Steering Committee; and (vii) to determine such other matters as allocated to the Joint Steering Committee hereunder.
The Joint Steering Committee shall not have the authority to: (w) modify or amend the terms and conditions of this Agreement; (x)
waive either Party’s compliance with the terms and conditions of this Agreement; (y) determine any issue in a manner that
would conflict with the express terms and conditions of this Agreement; or (z) amend the Research Program activities in a manner
that would increase the financial or other resource obligations imposed on the Company beyond the scope of those required under
the then current planned activities, and if such amendment would increase such financial or other resource obligations, then such
amendment must be mutually agreed to by the Parties in writing; provided that, for the avoidance of doubt if the work proposed
in the amendment to the Research Program activities could be performed with the financial or other resource obligations then currently
being funded by Merck and such work would not impose additional financial obligations on Company beyond the then current Research
Program activities, Company shall perform such work at no additional charge and the Research Program activities shall automatically
be deemed to be amended to include such work as proposed by the Joint Steering Committee.

 

		2.4.3	Meetings. During the Research Program Term, the Joint Steering Committee shall meet in accordance
with a schedule established by mutual written agreement of the Parties, but
no less frequently than once per Calendar Quarter, with the location for such meetings alternating between Company
and Merck facilities (or such other location may be determined by the Joint Steering Committee). Alternatively, the Joint Steering
Committee may meet by means of teleconference, videoconference or other similar communications equipment. Each Party shall bear
its own expenses related to the attendance of such meetings by its representatives.

 

		2.4.4	Disbandment of Joint Steering Committee. Upon completion (or earlier termination) of the
Research Program, the Joint Steering Committee shall be disbanded and shall have no further authority with respect to the activities
hereunder.

 

		2.5	Alliance Managers.

 

		2.5.1	Appointment. Each Party shall have the right to appoint an employee who shall oversee
interactions between the Parties for all matters related to this Agreement (each an “Alliance Manager”). Such
persons shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information,
and may serve as a single point of contact for any matters arising under this Agreement. The Alliance Managers shall have the right
to attend all Joint Steering Committee meetings as non-voting participants and may bring to the attention of the Joint Steering
Committee any matters or issues either of them reasonably believes should be discussed, and shall have such other responsibilities
as the Parties may mutually agree in writing. Each Party may designate different Alliance Managers by notice in writing to the
other Party.

 

		2.5.2	Responsibilities of the Alliance Managers. The Alliance Managers, if appointed, shall
have the responsibility of creating and maintaining a constructive work environment between the Parties. Without limiting the generality
of the foregoing, each Alliance Manager shall:

 

		(a)	identify and bring disputes and issues that may result in disputes (including without limitation
any asserted occurrence of a material breach by a Party) to the attention of the Joint Steering Committee in a timely manner, and
function as the point of first referral in all matters of conflict resolution;

 

    	 	14	 

     

    

 

		(b)	provide a single point of communication for seeking consensus both internally within the Parties’
respective organizations and between the Parties;

 

		(c)	plan and coordinate cooperative efforts, internal communications and external communications between
the Parties with respect to this Agreement; and

 

		(d)	take responsibility for ensuring that meetings and the production of meeting agendas and minutes
occur as set forth in this Agreement, and that relevant action items resulting from such meetings are appropriately carried out
or otherwise addressed.

 

		2.6	Patent Committee. The Parties hereby establish a committee to
facilitate the filing, prosecution and maintenance of Patent Rights as follows:

 

		2.6.1	Establishment. Within sixty (60) days after the Effective Date, the Parties shall establish
a patent committee (the “Patent Committee”) to discuss, oversee and coordinate the filing, prosecution, maintenance
and enforcement of Merck Patent Rights, Company Patent Rights and Joint Patent Rights; and the filing of Patent Rights on Information
and Inventions (with the exception of Other Information and Inventions which are not Joint Information and Inventions); and defense
against claims of infringement of Third Party patents related to the intellectual property licensed or practiced under this Agreement.
The Patent Committee will provide recommendations to the Parties regarding the filing, prosecution, maintenance and enforcement
of such Patent Rights and related intellectual property matters.

 

		2.6.2	Membership; Meetings. The Patent Committee shall be composed of one (1) employee from each
of Merck and Company knowledgeable in U.S. patent law and the technology areas that are the subject of this Agreement. The Patent
Committee shall meet, in person, by teleconference, or by video-teleconference, at least one (1) time per Calendar Quarter, or
more or less often as the Parties shall determine. In-person meetings shall alternate between Company and Merck locations within
the United States whenever possible unless otherwise agreed by the Parties. The first such meeting shall be within ninety (90)
days after the Effective Date. Any member of the Patent Committee may designate a substitute, who shall be an employee of the applicable
Party, to attend with prior written notice to the other Party. Ad hoc guests who are subject to written confidentiality obligations
at least as stringent as the provisions in Article 4 may be invited to Patent Committee meetings. Each Party may replace
its Patent Committee members with other of its employees with the qualifications set forth in this Section 2.6.2, at any
time, upon written notice to the other Party.

 

		2.6.3	Recommendations; Limitations on Patent Committee.  Recommendations of the Patent Committee
shall be made by consensus, with each Party having collectively one (1) vote in all decisions. The Patent Committee shall have
only such powers as are specifically delegated to it in this Agreement and such powers shall be subject to the terms and conditions
set forth herein. Without limiting the generality of the foregoing, the Patent Committee shall have no power to amend this Agreement,
the Research Program or any written Research plan. Recommendations where the Patent Committee is unable to reach a consensus are
determined as follows:

 

    	 	15	 

     

    

 

		(a)	Merck shall have final decision-making authority with respect to any dispute relating specifically
to Cue Biologics-Specific Information and Inventions, Cue Biologics Patent Rights, and Merck Other Information and Inventions;

 

		(b)	Company shall have final decision-making authority with respect to any dispute relating specifically
to Platform Information and Inventions, Platform Patent Rights, and Company Other Information and Inventions; and

 

		(c)	The Patent Committee shall seek to resolve disputes concerning recommendations on Joint Other Information
and Inventions. If the Patent Committee is unable to reach a consensus recommendation on a matter that relates to the Joint Other
Information and Inventions within thirty (30) days after it has met and attempted to reach such recommendation, then either Party
may refer such matter for resolution by nominated executives of each Party.

 

The Patent Committee
shall provide status updates to the Joint Steering Committee once per Calendar Quarter as long as the Joint Steering Committee
is in existence and, thereafter, to the Parties.

 

Company shall update
Schedule 1.1 and provide such updated schedule to the Patent Committee on a monthly basis.

 

		2.6.4	Duration of Patent Committee. The Patent Committee shall endure for the Term and, by mutual
agreement, beyond the Term.

 

		2.7	Exchange of Information. Following execution of this Agreement,
and during the term of the Research Program, Company shall on a quarterly basis and at least ten (10) days before each Joint Steering
Committee meeting disclose to Merck in English and in writing or in an electronic format, any: [***].
Notwithstanding the foregoing, the Information exchanged pursuant to this Section 2.7 or the subject of a Company representation
pursuant to Article 6 does not in any way limit the definition of Company Know-How as employed throughout the Agreement.

 

		2.8	Records and Reports.

 

		2.8.1	Records. Company shall maintain records, in sufficient detail and in good scientific manner
appropriate for patent and regulatory purposes, which shall fully and properly reflect all work done and results achieved in the
performance of the Research Program by Company.

 

		2.8.2	Copies and Inspection of Records. Merck shall have the right, during normal business hours
and upon reasonable notice, to inspect and copy all such records of Company referred to in Section 2.8.1. Merck shall maintain
such records and the information disclosed therein in confidence in accordance with Section 4.1. Merck shall have the right
to arrange for its employee(s) and/or consultant(s) involved in the activities contemplated hereunder to visit the offices and
laboratories of Company and any of its Third Party contractors as permitted under Section 2.2 during normal business hours
and upon reasonable notice, and to discuss the Research Program work and its results in detail with the technical personnel and
consultant(s) of Company. Upon request, Company shall provide copies of the records described in Section 2.8.1.

 

    	 	16	 

     

    

 

		2.8.3	Quarterly Reports. Within thirty (30) calendar days following the end of each Calendar Quarter
during the term of this Agreement, Company shall provide to Merck a written progress report in English which shall describe the
work performed to date on the Research Program, evaluate the work performed in relation to the goals of the Research Program and
provide such other information as may be required by the Research Program or reasonably requested by Merck relating to the progress
of the goals or performance of the Research Program. For clarity, all such reports shall be considered the confidential Information
of Merck.

 

		2.9	Research Information and Inventions. The entire right, title
and interest in:

 

		2.9.1	Company Information and Inventions shall be owned solely by Company;

 

		2.9.2	Merck Information and Inventions shall be owned solely by Merck; and

 

		2.9.3	Joint Information and Inventions shall be owned jointly by Company and Merck.

 

Company shall promptly disclose to
Merck in writing the development, making, conception or reduction to practice of Company Information and Inventions and Joint Information
and Inventions. For the purposes of determining ownership under this Section 2.9, inventorship shall be determined in accordance
with United States patent laws (regardless of where the applicable activities occurred). Subject to the licenses granted to the
other party under this Agreement and the other terms and conditions of this Agreement, each Party shall have the non-exclusive
right to exploit its interest in Joint Information and Inventions and Joint Patent Rights, and to grant licenses under its interest
in Joint Information and Inventions and Joint Patent Rights, as it deems appropriate, without the consent of, and without accounting
to, the other Party; provided, however, that for clarity, the foregoing joint ownership rights shall not be construed
as granting, conveying or creating any license or other rights to the other Party’s intellectual property, unless otherwise
expressly set forth in this Agreement; and further provided that, in the event that any Joint Patent Rights claim or cover
a Compound or the Manufacturing process therefor, Company shall not grant any license under its interest in such Joint Patent Rights
to any Third Party without Merck’s prior written consent.

 

		2.10	Research Program Term. The term of the Research Program shall
commence on the Effective Date and continue until the later of: (i) election of [****] Product Candidates; or (ii) [****] from the Effective Date, except as provided below in Section 2.10.1 or as otherwise stated herein.

 

		2.10.1	Extensions. The term of the Research Program may be extended by Merck at its sole discretion
for a total of [****] additional years on a year-by-year basis. To exercise each of these extensions, Merck shall provide
written notice of such request at least ninety (90) days prior to the expiration of the then current Research Program term. For
each extension exercised pursuant to this Section 2.10.1, the Parties shall work together to mutually agree on a revised
Research Program and Schedule 2.1. Such revised Research Program shall be encompassed within the definition of Research
Program for purposes of this Agreement.

 

		2.11	Exclusive Efforts.

 

		2.11.1	Cue Biologics, Compounds, Indication Specific Peptides. During the Research Program Term,
Company shall keep Merck informed of any Indication Specific Peptide or of any Cue Biologic or Compound that is Researched or Developed
for use in an Initial Indication. [***]

 

    	 	17	 

     

    

 

		2.11.2	Cue Platform Biologics. [***]

 

		2.11.3	Company Forbearance.

 

		2.11.3.1	From the Effective Date until the earlier of [***], Company hereby covenants
                                                                           and agrees that it will not alone or with Third Parties [***]. Company shall, and shall cause its Affiliates to, furthermore
                                                                           [****].

 

		2.11.3.2	From [***] to [***]. Company hereby covenants and agrees that it will not
alone or with Third Parties  [***]. Company shall, and shall cause
its Affiliates to, furthermore [***].

 

		2.11.4	[****].
From the Effective Date until [***], and subject to the provisions of Section 2.11.6 below relating to Company Candidates,
Company may.

 

    	 	18	 

     

    

 

		2.11.5	[****].

 

		 	 

 

		 	 

 

    	 	19	 

     

    

 

		2.11.6	[****]

 

 

 

    	 	20	 

     

    

 

		2.12	Compliance with Law and Ethical Business Practices.

 

		2.12.1	Company shall conduct the activities of the Research Program in accordance with all relevant applicable
laws, rules and regulations including, without limitation, all current governmental regulatory requirements concerning Good Laboratory
Practices. Company shall notify Merck in writing of any deviations from applicable regulatory or legal requirements if Company
becomes aware of any such deviation. Company hereby certifies that it has not and will not employ or otherwise use in any capacity
the services of any person or entity debarred under Section 21 USC 335a in performing any services hereunder. Company shall notify
Merck in writing immediately if any such debarment occurs or comes to its attention, and shall promptly remove any person or entity
so disbarred from performing any activity or function or capacity related to the Research Program. Merck shall have the right,
in its sole discretion, to terminate this Agreement immediately in the event that Company fails to promptly remove any such persons.

 

		2.12.2	Company acknowledges that Merck’s corporate policy requires that Merck’s business must
be conducted within the letter and spirit of the law. By signing this Agreement, Company agrees to conduct the services contemplated
herein in an ethical, reasonable and lawful manner.

 

		2.12.3	Specifically,
Company warrants that none of its employees, agents, officers or other members of its management are officials, officers, agents,
representatives of any government or international public organization. –NOTE: FOR A LIST OF "American
institutions of research, public international organizations and designations under the International Immunities Act"
SEE Section 316.20 at http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=d2739abeb6ca1764c5defa8607248f64&n=8y1.0.1.3.68&r=PART&ty=HTML#8:1.0.1.3.68.0.1.14
Company shall not make any payment, either directly or indirectly, of money or other assets, including but not limited to the
compensation Company derives from this Agreement (hereinafter collectively referred as a “Payment”), to government
or political party officials, officials of international public organizations, candidates for public office, or representatives
of other businesses or persons acting on behalf of any of the foregoing (hereinafter collectively referred as “Officials”)
where such Payment would constitute violation of any law. In addition regardless of legality, Company shall make no Payment either
directly or indirectly to Officials if such Payment is for the purpose of influencing decisions or actions with respect to the
subject matter of this Agreement or any other aspect of Merck’s business.

 

    	 	21	 

     

    

 

		2.12.4	Company acknowledges that no employee of Merck or its Affiliates shall have authority to give any
direction, either written or oral, relating to the making of any commitment by Company or its agents to any Third Party in violation
of terms of this or any other provisions of this Agreement.

 

		2.12.5	Company certifies to Merck that as of the date of this Agreement that Company has screened itself,
and its officers, directors and employees against the Exclusions Lists and that it has informed Merck whether Company, or any of
its officers or directors has been in Violation. After the execution of this Agreement, Company shall notify Merck in writing immediately
if any such Violation occurs or comes to its attention.

 

		2.12.6	Company’s failure to abide by the provisions of Section 2.12 shall be deemed a material
breach of this Agreement. In the event that Company fails to cure such failure within the time specified in Section 8.3.1(a)
after being notified by Merck of such failure, Merck may in such case and with immediate effect terminate this Agreement at its
sole discretion upon written notice to Company and without prejudice to any other remedies that may be available to Merck.

 

		2.12.7	Company shall indemnify and hold Merck and any of its Affiliates harmless from and against any
and all liabilities (including all costs and reasonable attorneys’ fees associated with defending against such claims) that
may arise by reason of the negligent or willful acts or omissions of Company or its agents which would constitute a violation of
Section 2.12.

 

		2.12.8	Company shall indemnify and hold Merck and any of its Affiliates harmless from and against any
and all liabilities (including all costs and reasonable attorneys’ fees associated with defending against such claims) that
may arise by reason of the careless, negligent or willful acts or omissions of Third Parties acting on Company’s behalf which
would constitute a violation of Section 2.12. [***]

 

		2.13	Use of Human Materials.
If any human cell lines, tissue, human clinical isolates or similar human-derived materials (“Human
Materials”) have been or are to be collected and/or used in the Research Program, Company represents and warrants:
(i) that it has complied, or shall comply, with all applicable laws, guidelines and regulations relating to the collection and/or
use of the Human Materials; and (ii) that it has obtained, or shall obtain, all necessary approvals and appropriate informed consents,
in writing, for the collection and/or use of such Human Materials. Company shall provide documentation of such approvals and consents
upon Merck’s request. Company further represents and warrants that such Human Materials may be used as contemplated in this
Agreement without any obligations to the individuals or entities (“Providers”)
who contributed the Human Materials, including, without limitation, any obligations of compensation to such Providers or any other
Third Party for the intellectual property associated with, or commercial use of, the Human Materials for any purpose.

 

    	 	22	 

     

    

 

		2.14	Animal Research. If animals are used in research hereunder, Company will comply with the
Animal Welfare Act or any other applicable local, state, national and international laws and regulations relating to the care and
use of laboratory animals. Merck encourages Company to use the highest standards, such as those set forth in the Guide for the
Care and Use of Laboratory Animals (NRC, 1996), for the humane handling, care and treatment of such research animals. Company hereby
certifies that it has and shall maintain current and valid accreditation from AAALAC during the Term. Any animals which are used
in the course of the Research Program, or products derived from those animals, such as eggs or milk, will not be used for food
purposes, nor will these animals be used for commercial breeding purposes.

 

Article
3  LICENSE; EXCHANGE OF INFORMATION; DEVELOPMENT AND COMMERCIALIZATION.

 

		3.1	License Grants.

 

		3.1.1	Company hereby grants to Merck an exclusive sublicense (even as to Company) in the Field and in
the Territory under Company’s rights in the Einstein Patent Rights and Einstein Know-How, with the right to grant and authorize
sublicenses, for any and all uses, including without limitation: (i) to make, have made or use Cue Biologics; (ii) to make, have
made, use, import, offer to sell and sell Compound(s) and/or Product(s); and (iii) to otherwise carry out activities contemplated
under this Agreement; all within the Field.

 

		3.1.2	Company hereby grants to Merck an exclusive license (even as to Company) in the Field and in the
Territory under Cue Patent Rights, Cue Know-How, and Company’s interest in Joint Patent Rights, with the right to grant and
authorize sublicenses, for any and all uses, including without limitation: (i) to make, have made or use Cue Biologics; (ii) to
make, have made, use, import, offer to sell and sell Compound(s) and/or Product(s); and (iii) to otherwise carry out activities
contemplated under this Agreement; all within the Field.

 

		3.1.3	[***]

 

		3.1.4	Notwithstanding the
scope of the exclusive sublicenses and licenses granted to Merck under Section 3.1.1 and Section 3.1.2, Company
shall retain the rights under the Company Know-How, Company Patent Rights and Joint Patent Rights during the Research Program Term
solely in connection with performing Company’s obligations under the Research Program in accordance with this Agreement to:
(i) research, develop, make, have made, sell, offer to sell, import and use in the Territory, Cue Biologics, Compounds, Products
and any invention claimed in or covered by Company Patent Rights or Joint Patent Rights; and (ii) use Company Know-How.

 

		3.1.5	[***]

 

		3.2	Non-Exclusive License Grant. In the event that either: (i) the making, have made or use
by Merck or its Related Parties of any Cue Biologics during the term of this Agreement; or (ii) the making, having made, use, import,
offer for sale and/or sale by Merck or its Related Parties of Compound or Product in the Territory would infringe a claim of an
issued letters patent that Company (or its Affiliate) Controls and which patents are not covered by the grant in Section 3.1,
Company hereby grants to Merck, to the extent Company is legally able to do so, a non-exclusive, sublicensable, royalty-free license
in the Territory under such issued letters patent for Merck and its Related Parties to conduct such activities with respect to
the Cue Biologics, Compounds and Products for all activities in the Field.

 

    	 	23	 

     

    

 

		3.3	No Implied Licenses. Except as specifically set forth in this Agreement, neither Party shall
acquire any license or other intellectual property interest, by implication or otherwise, in any Information disclosed to it under
this Agreement or under any patents or patent applications owned or Controlled by the other Party or its Affiliates.

 

		3.4	No Grant of Inconsistent Rights by Company. Company (and its
Affiliates) shall not assign, transfer, convey or otherwise grant to any Person or otherwise encumber (including through lien,
charge, security interest, mortgage, encumbrance or otherwise): (i) any rights to any Company Know-How, Company Patent Rights or
Company’s interest in Joint Patent Rights (or any rights to any intellectual property that would otherwise be included in
the Company Know-How, Company Patent Rights or Joint Patent Rights), in any manner that is inconsistent with or would interfere
with the grant of the rights or licenses to Merck hereunder; (ii) any rights to any Cue Biologic prior to the expiration of the
Research Program Term (provided that Company shall grant to Merck the rights to the Cue Biologics as set forth herein); or (iii)
any rights to any Compounds or Products (provided that Company shall grant to Merck the rights to the Compounds and Products as
set forth herein). Without limiting the foregoing, during the Term, (x) Company (and its Affiliates) shall not use (and shall not
grant to any Third Party the right to use) any Cue Biologics (prior to the expiration of the Research Program Term) or Compounds
or Products for any purposes (including the Research, Development, Manufacturing or Commercialization thereof), except for Company’s
performance of the activities to be performed by Company under the Research Program in accordance with this Agreement and (y) Company
(and its Affiliates) shall not provide or otherwise transfer to any Third Parties any Company Know-How which constitutes Cue Biologics-Specific
Information and Inventions, for use in the Field.

 

		3.5	Development and Commercialization. Merck shall use Commercially
Reasonable Efforts, at its own expense, to Research, Develop and Commercialize a Compound or Product. Company shall timely supply
adequate and sufficient amounts of Product Candidates through IND Enabling Studies for each Product Candidate. Merck shall reimburse
Company for its reasonable expenses in supplying such adequate and sufficient amounts. Following the Research Program Term, upon
Company’s written request which shall be no more frequently than once per year, Merck shall provide a written summary of
Merck’s activities in Researching, Developing and/or Commercializing a Compound or Product (“Progress Report”).

 

		3.6	Excused Performance. In addition to the provisions of Article
6, the obligations of Merck with respect to any Product under Section 3.5 are expressly conditioned upon the continuing
absence of any adverse condition or event relating to the safety or efficacy of the Compound or Product, and the obligation of
Merck to Research, Develop or Commercialize any such Compound or Product shall be delayed or suspended so long as in Merck’s
good faith determination any such condition or event exists. Where such adverse condition or event exists, Merck will provide written
notice as soon as practicable of a delay or suspension exercised under this Section 3.6.

 

    	 	24	 

     

    

 

		3.7	Regulatory Matters. In the event that Merck determines that any
regulatory filings for any Compounds and/or Products are required for any activities hereunder (including any activities under
the Research Program), including INDs, NDAs and other Marketing Authorizations (as applicable), then as between the Parties, Merck
(or its Affiliate or Related Party) shall have the sole right, in its discretion, to obtain such regulatory filings (in its (or
its Affiliate’s or its Related Party’s) name) and as between the Parties, Merck (or its Affiliate or its Related Party)
shall be the owner of all such regulatory filings. As between the Parties, Merck (or its Affiliate or Related Party) shall have
the sole right to communicate and otherwise interact with Regulatory Authorities with respect to the Compounds and/or Products
(including during the Research Program Term). For clarity, Company shall have no right to, and shall not, make any regulatory filings
related to any Compounds or Products or otherwise interact with any Regulatory Authorities with respect to the Compounds or Products.

 

		3.8	Sublicenses. Merck shall ensure that all sublicenses of the Cue
Patent Rights and Cue Know-How granted by Merck under this Agreement comport with the terms of this Agreement, and that all sublicenses
of the Einstein Patent Rights and Einstein Know-How granted by Merck under this Agreement comport with the terms of this Agreement
and the Amended and Restated Einstein License Agreement. 

 

Article
4  CONFIDENTIALITY AND PUBLICATION.

 

		4.1	Nondisclosure Obligation. All Information disclosed by one Party
to the other Party hereunder shall be maintained in confidence by the receiving Party and shall not be disclosed to any Third Party
or used for any purpose except as set forth herein without the prior written consent of the disclosing Party, except to the extent
that such Information:

 

		4.1.1	is known by the receiving Party at the time of its receipt, and not through a prior disclosure
by the disclosing Party, as documented by the receiving Party’s business records;

 

		4.1.2	is in the public domain by use and/or publication before its receipt from the disclosing Party,
or thereafter enters the public domain through no fault of the receiving Party;

 

		4.1.3	is subsequently disclosed to the receiving Party by a Third Party who may lawfully do so and is
not under an obligation of confidentiality to the disclosing Party;

 

		4.1.4	is developed by the receiving Party independently of Information received from the disclosing Party,
as documented by the receiving Party’s business records;

 

		4.1.5	is disclosed to governmental or other regulatory agencies in order to obtain patents on Inventions
in accordance with Article 7 herein or to gain or maintain approval to conduct clinical trials on Compound or Product or
to market Product, but such disclosure may be only to the extent reasonably necessary to obtain such patents or approvals;

 

		4.1.6	is deemed necessary by Merck to be disclosed to Related Parties, agent(s), consultant(s), and/or
other Third Parties for any and all purposes Merck and its Affiliates deem necessary or advisable in the ordinary course of business
to achieve the objectives of this Agreement on the condition that such Third Parties agree to be bound by confidentiality and non-use
obligations that substantially are no less stringent than those confidentiality and non-use provisions contained in this Agreement;
provided, however, that the term of confidentiality for such Third Parties shall be no less than ten (10) years; or

 

    	 	25	 

     

    

 

		4.1.7	is deemed necessary by counsel to the receiving Party to be disclosed to such Party’s attorneys,
independent accountants or financial advisors for the sole purpose of enabling such attorneys, independent accountants or financial
advisors to provide advice to the receiving Party, on the condition that such attorneys, independent accountants and financial
advisors agree to be bound by the confidentiality and non-use obligations contained in this Agreement; provided, however,
that the term of confidentiality for such attorneys, independent accountants and financial advisors shall be no less than ten (10)
years.

 

		4.1.8	is deemed necessary by the receiving Party to be disclosed to such Party’s executives, management
and other advisors, including but not limited to members of the Board of Directors and/or Scientific Advisory Board, consultants,
bankers, lenders, existing and prospective bona fide investors, and prospective merger and/or acquisition partners (“Representatives”)
on the following conditions: [***].

 

Any combination of features or disclosures
shall not be deemed to fall within the foregoing exclusions merely because individual features are published or available to the
general public or in the rightful possession of the receiving Party unless the combination itself and principle of operation are
published or available to the general public or in the rightful possession of the receiving Party.

 

If a Party is required by judicial
or administrative process (including a request for discovery received in an arbitration or litigation proceeding), or by a statute,
regulation or rule of law (e.g., securities laws, rules and regulations), to disclose information that is subject to the non-disclosure
provisions of this Section 4.1 or Section 4.2, such Party shall promptly inform the other Party of the disclosure
that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure obligations. Information
that is disclosed by judicial or administrative process shall remain otherwise subject to the confidentiality and non-use provisions
of this Section 4.1 and Section 4.2, and the Party disclosing information pursuant to law or court order shall take
all steps reasonably necessary, including without limitation obtaining an order of confidentiality, to ensure the continued confidential
treatment of such information. The Parties will consult and cooperate fully with each other on the provisions of this Agreement
to be redacted in any filings made by the Parties with the Securities and Exchange Commission or similar governmental agency in
the U.S. or abroad, or as otherwise required by law.

 

		4.2	Company Know-How. During the period from the Effective Date until achievement of Proof of
Mechanism for the first Cue Biologic, Company agrees to keep all Company Know-How specifically related to any Cue Biologic, Compound,
Product, Indication Specific Peptide, or any Peptide or biologic which is of utility for [****] confidential subject to Section 4.1. Upon achievement of Proof of Mechanism for the first Cue Biologic, Company
agrees to keep all Company Know-How specifically related to any Cue Biologic, Compound, Product, Indication Specific Peptide or
any Peptide or biologic which is of utility for [****] confidential subject to Section 4.1. In the event
that a Company Candidate is not designated as a Proposed Product Candidate pursuant to Section 2.11.6.3, then with respect
to such Company Know-How which is specifically related to to such Proposed Product Candidate (and not related to any other molecule
which is a subject of the Agreement) Company’s obligations of confidentiality shall cease.

 

    	 	26	 

     

    

 

		4.3	Publication. Each Party to this Agreement recognizes that the publication or disclosure of papers,
presentations, abstracts or any other written or oral presentations regarding results of and other information regarding the subject
matter of this Agreement, including the Research Program, may be beneficial to both Parties. Each Party also recognizes the mutual
interest in obtaining valid patent protection and in protecting business interests and trade secret information. Accordingly, except
for disclosures permitted pursuant to Section 4.1 each Party shall have the right to review and approve any paper or presentation
proposed for disclosure by the other Party which utilizes data related to the Research Program, Cue Biologic, Compound or Product
and/or includes confidential Information of the other Party. Before any such paper or presentation is disclosed, the Party proposing
disclosure shall deliver a complete copy to the other Party at least sixty (60) days prior to submitting the paper to a publisher
or making the presentation to a Third Party. The reviewing Party shall have the right (a) to propose modifications to the publication
or presentation for patent reasons, trade secret reasons or business reasons or (b) to request a reasonable delay in publication
or presentation in order to protect patentable information. If the reviewing Party requests a delay, the publishing Party shall
delay submission or presentation for a period of up to ninety (90) days as necessary to enable patent applications protecting each
Party's rights in such information to be filed in accordance with Article 7. Upon expiration of such ninety (90) days, the publishing
Party shall be free to proceed with the publication or presentation. Notwithstanding the foregoing, if the reviewing Party requests
modifications to the publication or presentation including the deletion of certain proprietary information, the publishing Party
shall edit such publication to prevent disclosure of trade secret or proprietary business information (including but not limited
to information related to Cue Biologics-Specific Information and Inventions) prior to submission of the publication or presentation.
The disclosing Party shall comply with any such requests of the reviewing Party.

 

		4.4	Publicity/Use of Names/Press Releases.
No disclosure of the existence, or the terms, of this Agreement may be made by either Party, and no Party shall use the name, trademark,
trade name or logo of the other Party, its Affiliates or their respective employee(s) in any publicity, promotion, news release
or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party,
except as may be required by law. If a Party is required by a statute, regulation or rule of law (e.g., securities laws, rules
and regulations), to disclose the existence, or the terms, of this Agreement or the name, trademark, trade name or logo of the
other Party, such Party shall promptly inform the other Party of the disclosure that is being sought and provide for a period of
at least ten (10) days, or if the period provided by statute, regulation or rule of law is less than ten (10) days, the maximum
period allowable thereunder in order to provide the other Party an opportunity to review the disclosure, provide comments, and
challenge or limit the disclosure obligations. Information that is disclosed shall remain otherwise subject to the confidentiality
and non-use provisions of Section 4.1 and Section 4.2, and the Party disclosing information shall take all steps
reasonably necessary, to ensure the continued confidential treatment of such information. The Parties will furthermore consult
and cooperate fully with each other on the provisions of this Agreement to be redacted in any filings made by the Parties with
the Securities and Exchange Commission or similar governmental agency in the U.S. or abroad, or as otherwise required by law.

 

Article
5  PAYMENTS; ROYALTIES AND REPORTS

 

		5.1	License Fee. In consideration
for the licenses and other rights granted to Merck herein under the Company Patent Rights, Company
Know-How and Company’s interest in Joint Patent Rights, upon the terms and conditions contained herein, Merck
shall pay to Company US$ 2,500,000 (two million five hundred thousand) payable within thirty (30) days after the Effective Date.
Company shall use these funds to pay for Contract Research as that term is defined in the Amended and Restated Einstein License
Agreement.

 

    	 	27	 

     

    

 

		5.2	Milestone Payments.
 Subject to the terms and conditions of this Agreement, Merck shall pay to Company the following milestone payments,
for which Merck or any Related Party achieves, or Company achieves and Merck confirms, the following milestone events hereunder
during the Term:

 

		5.2.1	Research Collaboration Milestones.

 

	 	 	Milestone Event	 	Payment to Company
	1.	 	[***]	 	[***]
	2.	 	[***]	 	[***]

 

		5.2.2	Development and Regulatory Milestones.

 

	 	 	Milestone Event	 	Payment to Company
	3.	 	[***]	 	[***]
	4.	 	[***]	 	[***]
	5.	 	[***]	 	[***]
	6.	 	[***]	 	[***]
	7.	 	[***]	 	[***]
	8.	 	[***]	 	[***]
	9.	 	[***]	 	[***]

 

		5.3	Merck shall notify Company in writing within sixty (60)
                                                                                                 days following the achievement of each milestone set forth in Section 5.2.1 and Section 5.2.2. With respect to
                                                                                                 the achievement of a milestone under Section 5.2.1 and milestones 1-9 under Section 5.2.2, Merck shall make the
                                                                                                 appropriate milestone payment within sixty (60) days after the achievement of such milestone. [***].
                                                                                                 The milestone payments pursuant to Section 5.2.1 and Section 5.2.2 shall be payable only upon the initial
                                                                                                 achievement of such milestone [****]; but in no event shall such milestone payment be paid [****]. Such milestones are independent of the royalty payments due under Section 5.4 and shall not
                                                                                                 offset or affect the payment of any royalty payments due under Section 5.4.

 

    	 	28	 

     

    

 

		5.4	Royalties.

 

		5.4.1	Royalties Payable By Merck. Subject to the terms and conditions of this Agreement, Merck
shall pay Company royalties, calculated on a Product-by-Product basis, as set forth in Section 5.4.

 

		(a)	Patent Royalties. Subject to the provisions of Section 5.4.1(b), Merck shall pay
Company royalties in an amount equal to the following percentage of Net Sales of Products by Merck or its Related Parties where
the sale of Product would infringe a Valid Patent Claim in the country of sale:

 

		(1)	[***] of Net Sales in the Territory in each Calendar Year up to and including [***];

 

		(2)	[***] of Net Sales in the Territory in each Calendar Year for the portion of Net
Sales exceeding [***] up to and including [***]; and

 

		(3)	[***] of Net Sales in the Territory in each Calendar Year for the portion of Net
Sales exceeding [***].

 

		(b)	Know-How Royalty. Notwithstanding the provisions of Section 5.4.1(a), in countries
where the sale of Product by Merck or its Related Parties would not infringe a Valid Patent Claim, Merck shall pay royalty rates
that shall be set at [***] of the applicable royalty rate determined according to Section 5.4.1(a). Such royalties shall
be calculated after first calculating royalties under Section 5.4.1(a).

 

		(c)	Royalty tiers pursuant to Section 5.4.1(a) and Section 5.4.1(b) shall be calculated
based on Net Sales of each Product in the Territory, provided that the determination of whether the royalty shall be calculated
under Section 5.4.1(a) or Section 5.4.1(b) shall be determined on a country-by-country basis. Royalties on each Product
at the rates set forth above shall continue on a country-by-country basis until the expiration of the later of: (i) the last-to-expire
Valid Patent Claim claiming the Compound; or (ii) for a period of ten (10) years after First Commercial Sale of such Product in
such country (the “Royalty Period”).

 

		(d)	All royalties are subject to the following conditions:

 

		(i)	that only one royalty shall be due with respect to the same unit of Product;

 

		(ii)	that no royalties shall be due upon the sale or other transfer among Merck or its Related Parties,
but in such cases the royalty shall be due and calculated upon Merck’s or its Related Party’s Net Sales to the first
independent Third Party;

 

		(iii)	no royalties shall accrue on the sale or other disposition of Product by Merck or its Related Parties
for use in a Clinical Trial; and

 

		(iv)	no royalties shall accrue on the disposition of Product in reasonable quantities by Merck or its
Related Parties as samples (promotion or otherwise) or as donations (for example, to non-profit institutions or government agencies
for a non-commercial purpose).

 

    	 	29	 

     

    

 

		5.4.2	Change in Sales Practices. The Parties acknowledge that during the term of this Agreement,
Merck’s sales practices for the marketing and distribution of Product may change to the extent to which the calculation of
the payment for royalties on Net Sales may become impractical or even impossible. In such event the Parties agree to meet and reasonably
discuss in good faith new ways of compensating Company to the extent currently contemplated under Section 5.4.1.

 

		5.4.3	Royalties for [****]. In those cases in which [****], the royalty obligations of this Section 5.4 shall be applicable
to the compensation and/or other amount of consideration received by Merck [****].

 

		5.4.4	Compulsory Licenses. If a compulsory license is granted to a Third Party with respect to
Compound or Product in any country in the Territory with a royalty rate lower than the royalty rate provided by Section 5.4.1,
then the royalty rate to be paid by Merck on Net Sales in that country under Section 5.4.1 shall be reduced to the rate
paid by the compulsory licensee.

 

		5.4.5	[***]

 

		5.4.6	Royalty Rates. Notwithstanding any provision in this Agreement, where a royalty payment
is due in a particular country, in no event shall Merck pay royalty rates on Net Sales of any Product in such country that are
less than [***]. Accordingly, [***] the royalty rate can under no circumstance go lower than [***].

 

		5.5	Reports; Payment of Royalty.
During the term of this Agreement following the First Commercial Sale of a Product, Merck shall furnish to Company a quarterly
written report for the Calendar Quarter showing the Net Sales of all Products subject to royalty payments sold by Merck and its
Related Parties in the Territory during the reporting period and the royalties payable under this Agreement. Subject to the provisions
of Section 9.2.2, if applicable, such reports shall be sufficiently detailed so as to permit company to independently determine
the accuracy of the amount of royalties paid. Reports shall be due on the sixtieth (60th) day following the close of each Calendar
Quarter. Royalties shown to have accrued by each royalty report shall be due and payable on the date such royalty report is due.
Merck shall keep complete and accurate records in sufficient detail to enable the royalties payable hereunder to be determined.

 

		5.6	Audits.

 

		5.6.1	Upon the written request of Company and not more than once in each Calendar Year, Merck shall permit
an independent certified public accounting firm of nationally recognized standing selected by Company and reasonably acceptable
to Merck, at Company’s expense, to have access during normal business hours to such of the records of Merck as may be reasonably
necessary to verify the accuracy of the royalty reports hereunder for any Calendar Year ending not more than twenty-four (24) months
prior to the date of such request. The accounting firm shall disclose to Company only whether the royalty reports are correct or
incorrect and the amount of any discrepancy. No other information shall be provided to Company. The accounting firm shall be given
copies of all documents needed to accurately perform the accounting, with all provisions and terms necessary to accurately perform
the accounting being unredacted.

 

    	 	30	 

     

    

 

		5.6.2	If such accounting firm correctly identifies an underpayment by Merck during such period, then
Merck shall pay to Company the amount of the discrepancy within thirty (30) days of the date Company delivers to Merck such accounting
firm’s written report so correctly concluding, or as otherwise agreed upon by the Parties. The fees charged by such accounting
firm shall be paid by Company, except in the situation that the accounting firm determines that Merck has underpaid by the greater
of [***] or [***] the royalties it owed for any Calendar Year reviewed by the accounting firm. If such accounting firm correctly
identified an overpayment by Merck during such period, then such overpayment shall be withheld from a next payment due from Merck
to Company.

 

		5.6.3	Merck shall include in each sublicense granted by it pursuant to this Agreement a provision requiring
the sublicensee to make reports to Merck, to keep and maintain records of sales made pursuant to such sublicense and to grant access
to such records by Company’s independent accountant to the same extent required of Merck under this Agreement.

 

		5.6.4	Upon the expiration of twenty-four (24) months following the end of any Calendar Year, the calculation
of royalties payable with respect to such Calendar Year shall be binding and conclusive upon Company, and Merck and its Related
Parties shall be released from any liability or accountability with respect to royalties for such Calendar Year.

 

		5.6.5	Company shall treat all financial information subject to review under this Section 5.6 or
under any sublicense agreement in accordance with the confidentiality and non-use provisions of this Agreement, and shall cause
its accounting firm to enter into an acceptable confidentiality agreement with Merck and/or its Related Parties obligating it to
retain all such information in confidence pursuant to such confidentiality agreement.

 

		5.7	Payment Exchange Rate. All payments to be made by Merck to Company
under this Agreement shall be made in United States dollars and may be paid by check made to the order of Company or bank wire
transfer in immediately available funds to such bank account in the United States as may be designated in writing by Company from
time to time. In the case of sales outside the United States, the rate of exchange to be used in computing the monthly amount of
currency equivalent in United States dollars due Company shall be made at the monthly rate of exchange utilized by Merck in its
worldwide accounting system. 

 

		5.8	Income Tax Withholding. Company shall be liable for all income
and other taxes (including interest) (“Taxes”) imposed upon any payments made
by Merck to Company under this Article 5 (“Agreement Payments”). If
applicable laws, rules or regulations require the withholding of Taxes because of Company’s tax obligations, Merck shall
make such withholding payments and shall subtract the amount thereof from the Agreement Payments. For clarity, Merck shall not
deduct from Agreement Payments any Taxes withheld by Merck to satisfy Merck’s tax obligations. Merck shall submit to Company
appropriate proof of payment of the withheld Taxes as well as the official receipts within a reasonable period of time. Merck shall
provide Company reasonable assistance in order to allow Company to obtain the benefit of any present or future treaty against double
taxation which may apply to the Agreement Payments.

 

    	 	31	 

     

    

 

Article
6 REPRESENTATIONS AND WARRANTIES

 

		6.1	Representations and Warranties of Each
Party. Each Party represents and warrants to the other Party that as
of the Effective Date:

 

		6.1.1	such Party is duly organized and validly existing under the laws of the state or jurisdiction of
its organization and has full corporate right, power and authority to enter into this Agreement and to perform its obligations
hereunder;

 

		6.1.2	the execution and delivery of this Agreement and the consummation of the transactions contemplated
hereby have been duly authorized by the necessary corporate actions of such Party. This Agreement has been duly executed by such
Party. This Agreement and any other documents contemplated hereby constitute valid and legally binding obligations of such Party
enforceable against it in accordance with their respective terms, except to the extent that enforcement of the rights and remedies
created thereby is subject to bankruptcy, insolvency, reorganization, moratorium and other similar laws of general application
affecting the rights and remedies of creditors; and

 

		6.1.3	the execution, delivery and performance by such Party of this Agreement and any other agreements
and instruments contemplated hereunder will not: (i) in any respect violate any statute, regulation, judgment, order, decree or
other restriction of any governmental authority to which such Party is subject; (ii) violate any provision of the corporate charter,
by-laws or other organizational documents of such Party; or (iii) constitute a material violation or breach by such Party of any
provision of any material contract, agreement or instrument to which such Party is a party or to which such Party may be subject
although not a party.

 

		6.2	Company Representations and Warranties.
Company represents and warrants to Merck that as of the date of this Agreement:

 

		6.2.1	all Patent Rights within the Company Patent Rights are in full force and effect, and, to the best
of Company’s knowledge, the Company Patent Rights and Company Know-How exist and are not invalid or unenforceable, in whole
or in part;

 

		6.2.2	it has the full right, power and authority to enter into this Agreement, to perform the activities
hereunder, including the Research Program, and to grant the license and sublicense granted hereunder (including under Article
3);

 

		6.2.3	it (and its Affiliates) has not prior to the Effective Date: (i) assigned, transferred, conveyed
or otherwise encumbered its right, title and interest in Company Patent Rights or Company Know-How; or (ii) otherwise granted any
rights to any Third Parties that would conflict with the rights granted to Merck hereunder;

 

		6.2.4	it is the sole and exclusive owner or licensee of the Cue Patent Rights and Cue Know-How, all of
which are (and shall be, in the case of Company Information and Inventions) free and clear of any liens, charges and encumbrances,
and no other person, corporate or other private entity, or governmental entity or subdivision thereof, has or shall have any claim
of ownership whatsoever with respect to the Cue Patent Rights and Cue Know-How;

 

    	 	32	 

     

    

 

		6.2.5	to the best of Company’s knowledge, it is the sole and exclusive licensee of the Einstein
Patent Rights and Einstein Know-How, all of which are free and clear of any liens, charges and encumbrances, and no other person,
corporate or other private entity, or governmental entity or subdivision thereof, has or shall have any claim of ownership whatsoever
with respect to the Einstein Patent Rights and Einstein Know-How, with the exception that Company is aware that the United States
Government has sponsored certain related research of Albert Einstein and may have certain rights in any subject inventions resulting
therefrom;

 

		6.2.6	to the best of Company’s knowledge, the exercise of the license granted to Merck under the
Company Patent Rights and Company Know-How, including without limitation the Research, Development, Manufacture, use, sale and
import of Cue Biologics, Compounds and Products do not interfere with or infringe any intellectual property rights owned or possessed
by any Third Party other than Albert Einstein;

 

		6.2.7	there are no claims, judgments or settlements against or owed by Company (or any of its Affiliates)
and no pending or threatened claims or litigation relating to the Company Patent Rights and Company Know-How;

 

		6.2.8	to the best of Company’s knowledge, Company has disclosed to Merck all reasonably relevant
information which Company reasonably believes to be necessary for Merck to accomplish the goals of the Research Program and any
additional information requested by Merck regarding: (i) the Cue Biologics, Compounds or Products; and/or (ii) the Company Patent
Rights and Company Know-How licensed under this Agreement, including: (a) any licenses and material agreements related to the Company
Patent Rights, Company Know-How, Cue Biologics, Compounds and/or Products; and (b) and safety or efficacy information related to
the Cue Biologics, Compounds and/or Products;

 

		6.2.9	Company has disclosed to Merck the existence of any patent opinions related to the Company Patent
Rights and Company Know-How licensed under this Agreement;

 

		6.2.10	neither it nor any of its Affiliates has received any written notification from a Third Party that
the Research, Development, Manufacture, use, sale or import of Cue Biologics, Compounds or Products infringes or misappropriates
the Patent Rights or know-how owned or controlled by such Third Party, and Company has no knowledge that a Third Party has any
basis for any such claim;

 

		6.2.11	Company has complied with all existing country-specific laws and regulations involving inventor
remuneration associated with the Company Patent Rights, including Article 6 of the Third Amendment of Chinese Patent Law;

 

		6.2.12	Schedule 1.1 sets forth a true, correct and complete list of Company Patent Rights existing
as of the Effective Date and such schedule contains all application numbers and filing dates, registration numbers and dates, jurisdictions
and owners. The Company Patent Rights and Company Know-How constitute all intellectual property owned or otherwise controlled (through
license or otherwise) by Company (or any of its Affiliates) as of the Effective Date that are necessary or useful for (or otherwise
used by Company or any of its Affiliates in connection with), the Cue Biologics, Compounds and/or Products or the Research, Development,
Manufacture, Commercialization and/or use thereof;

 

    	 	33	 

     

    

 

		6.2.13	to the best of Company’s knowledge, Company has disclosed to Merck all material information
and data which Company reasonably believes to be necessary for Merck to accomplish the goals of the Research Program and any additional
information requested by Merck, in each case related to the Research Program and/or any Cue Biologics, Compounds or Products, regardless
of whether such data and information would have a positive, negative or neutral impact on the potential commercial, scientific
or strategic value or attractiveness of the Research Program, any Cue Biologics, Compounds or Products;

 

		6.2.14	Company has obtained all necessary consents, approvals and authorizations of all governmental authorities
and other Persons required to be obtained by it as of the Effective Date, as applicable, in connection with the execution, delivery
and performance of this Agreement;

 

		6.2.15	neither Company nor any of its Affiliates has obtained, or filed for, any INDs, NDAs or Marketing
Authorizations for any Cue Biologics, Compounds or Products, and, to the best of Company’s knowledge, no other Person has
obtained, or filed for, any INDs, NDAs or Marketing Authorizations for any Cue Biologics, Compounds or Products;

 

		6.2.16	to the best of Company’s knowledge, Company (and its Affiliates) has not employed or otherwise
used in any capacity, and will not employ or otherwise use in any capacity, the services of any Person debarred under United States
law, including under Section 21 USC 335a or any foreign equivalent thereof, with respect to the Cue Biologics, Compounds or Products
or otherwise in performing any portion of the Research Program.

 

		6.2.17	to the best of Company’s knowledge, all research and development (including non-clinical
studies) related to the Cue Biologics, Compounds and/or Products prior to the Effective Date has been conducted in accordance with
all Applicable Laws;

 

		6.2.18	except for the Third Party licenses and agreements resulting from the receipt of certain grants
by Albert Einstein from the United States Government, there are no agreements (including any licenses), written or oral, granting
any licenses or other rights to (or from) Company (or any of its Affiliates) relating to the Cue Biologics, Compounds or Products
or the Company Know-How or Company Patent Rights;

 

		6.2.19	with respect to each Third Party license: (i) it is in full force and effect; (ii) neither Company
nor any of its Affiliates is in breach thereof; (iii) neither Company nor any of its Affiliates has received any notice of breach
or notice of threatened breach thereof; and (iv) neither Company nor any of its Affiliates has received any notice from the counterparty
to such Third Party license of intent to reduce the scope of the field thereof or render any of the licenses thereunder non-exclusive,
and no event, act or omission has occurred which could give rise to the right of the counterparty to such Third Party license to
reduce the scope of the field thereof or render any of the licenses thereunder non-exclusive;

 

		6.2.20	to the best of Company’s knowledge, all information and data provided by or on behalf of
Company to Merck on or before the Effective Date in contemplation of this Agreement was and is true and accurate and complete in
all material respects, and Company has not intentionally disclosed, failed to disclose, or cause to be disclosed, any information
or data that would reasonably be expected to cause the information and data that has been disclosed to be misleading in any material
respect; and

 

    	 	34	 

     

    

 

		6.2.21	it has or ensures that it will have the resources and capabilities to do the work contemplated
by the Research Program.

 

For purposes of
the above representations, the phrase “to the best of Company’s knowledge” means that the employee(s) of the
Company with responsibility for the matter have conducted a reasonable inquiry regarding such matter.

 

		6.3	Company Third Party License Agreements Representations, Warranties and Covenants. Company
represents and warrants to Merck that it has provided to Merck as of the Effective date a true, correct and complete copy of each
relevant Company Third Party license agreements, and each such copy includes any and all amendments, restatements, side letters,
and other modifications thereto, as each such Company Third Party license agreement is in effect as of the Effective Date. Company
further covenants and agrees that during the Term, (a) it shall satisfy all of its obligations under (including making all payments),
and take all steps to maintain in full force and effect, each such relevant Company Third Party license agreements; (b) it will
not assign (except an assignment to a party to which this Agreement has been assigned as permitted under Section 9.2), amend,
restate, amend and restate, terminate in whole or in part, or otherwise modify any of the Company Third Party license agreements
necessary or useful to Merck’s exercise of the rights granted in this Agreement without the prior written consent of Merck;
(c) it will provide Merck with prompt notice of any claim of a breach under any of the Company Third Party license agreements or
notice of termination of any of the Company Third Party license agreements, made by either Company or the counterparty to such
Company Third Party license agreement (or any party acting on behalf of such counterparty); and, (d) it will promptly send to Merck
copies of all other material correspondence to or from the counterparty to such Company Third Party license agreement related to
such Company Third Party license agreement. For the purposes of clarity, Company (and not Merck) shall be responsible for all of
the financial and other obligations of Company (and/or any of its Affiliates) under any of the Company Third Party license agreements,
including any and all financial obligations thereunder with respect to Net Sales of Merck and its Related Parties. Merck shall
have the right, in its sole discretion, to terminate this Agreement immediately upon written notice to Company pursuant to Section
8.3, in the event that Company is in breach of this Section 6.3.

 

Article
7  PATENT PROVISIONS.

 

		7.1	[****]

 

		 	 

 

    	 	35	 

     

    

 

 

		(a)	Merck shall have the sole right to file, prosecute, maintain and defend patent applications on
Merck Information and Inventions (“Merck Other Information and Inventions”);

 

		(b)	Company shall have the sole right to file, prosecute, maintain and defend patent applications on
Company Information and Inventions (“Company Other Information and Inventions”); and

 

		(c)	The Patent Committee will review proposed patent filings pertaining to Joint Other Information
and Inventions. A Party that believes that a patent application should be filed regarding any Joint Information and Inventions
which constitute Other Information and Inventions (“Joint Other Information and Inventions”) shall bring the
matter to the attention of the Patent Committee and the Patent Committee shall discuss how to proceed. If Merck takes the lead
in filing and prosecuting the application, then the Parties shall follow the general procedure described in Section 7.1.1.
If Company takes the lead in filing and prosecuting the application, then the Parties shall follow the general procedure described
in Section 7.1.2. If both Parties agree that a patent application regarding any Joint Information and Inventions should
be filed, then the Parties will split the costs evenly or as otherwise agreed. If only one Party believes that a patent application
regarding any Joint Information and Inventions should be filed, then that Party shall bear all costs unless the Parties agree otherwise.

 

		7.1.4	Patent Term Extension. The
Parties shall cooperate fully with each other to provide necessary information and assistance, as the other Party may reasonably
request, in obtaining patent term extension or supplemental protection certificates or their equivalents in any country in the
Territory where applicable to Company Patent Rights and Joint Patent Rights. In the event that elections with respect to obtaining
such patent term extension are to be made, Merck shall have the right to make the election and Company agrees to abide by such
election.

 

		7.1.5	Other Cooperation. The Parties agree to cooperate fully and provide any information and
assistance that either may reasonably request for the filing, prosecution and maintenance of Company Patent Rights and Joint Patent
Rights, including but not limited to the preparation and filing of any terminal disclaimers and other documents required to procure
and preserve the protections under Applicable Law for all Company Patent Rights and Joint Patent Rights relevant to a Compound
or Product. The Parties further agree to take reasonable actions to maximize the protections available under the safe harbor provisions
of 35 U.S.C. 102(c) for U.S. patents and patent applications.

 

		7.1.6	Filing, Prosecution and Maintenance Expenses. Unless stated otherwise herein, with respect
to all filing, prosecution and maintenance activities under this Section 7.1, the filing and/or prosecuting Party shall
be responsible for payment of all costs and expenses related to such activities.

 

		7.1.7	Inventor Remuneration. Company shall comply with all applicable country-specific inventor
remuneration laws and regulations, including Article 6 of the Third Amendment of Chinese Patent Law associated with Company
Patent Rights and Joint Patent Rights when inventor remuneration obligations are triggered by an employee of Company and/or its
Affiliates, or a Third Party acting on behalf of Company and/or its Affiliates.

 

    	 	36	 

     

    

 

		7.2	Interference, Derivation, Opposition, Reexamination, Reissue, Supplemental Examination, Inter
Partes Review and Post-Grant Review Proceedings.

 

		[****]	 

 

		 	 

 

    	 	37	 

     

    

 

		7.2.3	Cooperation. In connection with any administrative proceeding under Section 7.2.1
or Section 7.2.2, Merck and Company shall cooperate fully and provide each other with any information or assistance that
either may reasonably request. The Parties shall keep each other informed of developments in any such action or proceeding, including
the status of any settlement negotiations and the terms of any offer related thereto. For any proceeding not controlled by Merck,
Company shall obtain prior approval from Merck of any settlement offer or settlement agreement. For any proceeding specifically
related to Platform Information and Inventions which is not controlled by Company, Merck shall obtain prior approval from Company
of any settlement offer or settlement agreement.

 

		7.2.4	Expenses. The Party controlling any administrative proceeding pursuant to Section 7.2.1
and Section 7.2.2 shall bear all expenses related thereto, unless the Parties agree otherwise.

 

		7.3	Enforcement and Defense.

 

		7.3.1	[****]

 

		7.3.2	The Party having the first right to initiate and prosecute legal action pursuant to Section
7.3.1 shall promptly inform the other Party if it elects not to exercise its first right under Section 7.3.1 to initiate
and prosecute legal action, and the other Party shall thereafter have the right to either initiate and prosecute such action or
to control the defense of such declaratory judgment action in its name and, if necessary, the name of the other Party. The costs
of any agreed-upon course of action to terminate infringement of Company Patent Rights or Joint Patent Rights or misappropriation
or misuse of Company Know-How, including without limitation the costs of any legal action commenced or the defense of any declaratory
judgment, shall be paid by the Party initiating and/or prosecuting the action. Each Party shall have the right to be represented
by counsel of its own choice.

 

    	 	38	 

     

    

 

		7.3.3	For any action to terminate any infringement of Company Patent Rights or Joint Patent Rights or
any misappropriation or misuse of Company Know-How pursuant to Section 7.3.1, in the event that a Party is unable to initiate
or prosecute such action solely in its own name, the other Party will join such action voluntarily and will execute and cause its
Affiliates to execute all documents necessary for the Party to initiate litigation to prosecute and maintain such action under
this Section 7.3. In connection with any action or potential action, Merck and Company will cooperate fully and will provide
each other with any information or assistance that either may reasonably request, including cooperating with regard to any pre-litigation
review of the Company Patent Rights and Joint Patent Rights. Each Party shall keep the other informed of developments in any action
or proceeding. For any proceeding not controlled by Merck, Company shall obtain prior approval from Merck of any settlement offer
or settlement agreement. For any proceeding specifically related to Platform Information and Inventions not controlled by Company,
Merck shall obtain prior approval from Company of any settlement offer or settlement agreement.

 

		7.3.4	Any recovery obtained by either or both Merck and Company in connection with or as a result of
any action contemplated by this Section 7.3, whether by settlement or otherwise, shall be shared in order as follows:

 

		(a)	the Party which initiated and prosecuted the action shall recoup all of its costs and expenses
incurred in connection with the action;

 

		(b)	the other Party shall then, to the extent possible, recover its costs and expenses incurred in
connection with the action; and

 

		(c)	the amount of any recovery remaining shall then be allocated between the Parties on a pro rata
basis taking into consideration the relative economic losses suffered by each Party.

 

		7.3.5	Company shall inform Merck of any matter of which it becomes aware concerning the submission of
an application to the U.S. Food & Drug Administration under Section 351(k) of the U.S. Public Health Services Act (42 USC 262(k)),
or to a similar agency under any similar provisions in a country in the Territory, seeking approval of a biosimilar or interchangeable
biological product with regard to which Merck is a reference product sponsor involving Company Patent Rights or Joint Patent Rights
(“Biosimilar Application”). Company shall provide Merck with the unopened Biosimilar Application within three (3) days
of receipt. Notwithstanding the foregoing provisions of Article 7, Merck shall have the sole right, in its discretion, to
control any legal action and any activity taken to resolve a dispute with respect to any infringement of Company Patent Rights
or Joint Patent Rights with respect to any Biosimilar Application, including selection of any patents for listing under 42 U.S.C.
§262(l), and Company shall have no rights in connection therewith. For any action with respect to any infringement of Company
Patent Rights or Joint Patent Rights with respect to any Biosimilar Application, in the event that Merck is unable to initiate
or prosecute such action solely in its own name, Company will join such action voluntarily and will execute and cause its Affiliates
to execute all documents necessary for Merck to initiate, prosecute and maintain such action. In connection with any action, Company
shall cooperate with Merck and provide Merck with information and assistance that Merck may reasonably request, including as defined
in Section 7.3.3.

 

    	 	39	 

     

    

 

Article
8  TERM AND TERMINATION

 

		8.1	Term and Expiration. This
Agreement shall be effective as of the Effective Date and unless terminated earlier pursuant to Section 8.2 or Section
8.3, this Agreement shall continue in full force and effect until one or more Products has received Marketing Authorization
and, thereafter, until expiration of all royalty obligations hereunder. In the event that [***].

 

		8.2	Termination by Merck. Notwithstanding
anything contained herein to the contrary, Merck shall have the right to terminate this Agreement at any time in its sole discretion
by giving thirty (30) days’ advance written notice to Company. For the avoidance of doubt, termination by Merck under this
Section 8.2 can be effected only through a written notice specifically referring to this Section 8.2. No later than
thirty (30) days after the effective date of such termination, each Party shall return or cause to be returned to the other Party
all Information in tangible form received from the other Party and all copies thereof; provided, however, that each
Party may retain one copy of Information received from the other Party in its confidential files for record purposes. In the event
of termination under this Section 8.2: (i) each Party shall pay all amounts then due and owing as of the termination date;
and (ii) except for the surviving provisions set forth in Section 8.4, the rights and obligations of the Parties hereunder
shall terminate as of the date of such termination; provided, however, that upon payment of the License Fee pursuant
to Section 5.1 Merck shall have a fully paid-up non-exclusive license under Company Information and Inventions and Company’s
interest in Joint Information and Inventions to [***]. Upon termination, the Parties shall confer to determine how the Joint Patent
Rights will be addressed.

 

		8.3	Termination for Cause.

 

		8.3.1	Cause for Termination. This Agreement may be terminated at any time during the term
of this Agreement:

 

		(a)	upon written notice by either Party if the other Party is in breach of its material obligations
hereunder by causes and reasons within its control and has not cured such breach within ninety (90) days after notice requesting
cure of the breach; provided, however, in the event of a good faith dispute with respect to the existence of a material
breach, the ninety (90) day cure period shall be tolled until such time as the dispute is resolved pursuant to Section 9.7;
or

 

		(b)	by either Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership
proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party; provided,
however, that in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if
the Party consents to the involuntary bankruptcy or such proceeding is not dismissed within ninety (90) days after the filing thereof.

 

		8.3.2	Effect of Termination for Cause on License.

 

		(a)	If either Merck or Company terminates this Agreement under Section 8.3.1(a) or Section
8.3.1(b), then [***] shall terminate as of such termination date and each Party shall, within thirty (30) days after
the effective date of such termination, return or cause to be returned to the other Party all Information of the other Party in
tangible form and substances or compositions delivered or provided by the other Party, as well as any other material provided by
the other Party in any medium; provided, however, that each Party may retain one copy of Information received from
the other Party in its confidential files for record purposes.

 

    	 	40	 

     

    

 

		(b)	[***].

 

		(c)	Upon termination of this Agreement by Merck pursuant to Section 8.2, or by Company pursuant
to Section 8.3.1(a), Merck and its Affiliates, sublicensees and distributors shall be entitled, during the twelve (12) month
period immediately following the effective date of termination, to finish any work-in-progress and to sell any Product or Compound
remaining in inventory, in accordance with the terms of this Agreement.

 

		(d)	If this Agreement is terminated by Merck pursuant to Section 8.3.1(b) due to the rejection
of this Agreement by or on behalf of Company under Section 365 of the United States Bankruptcy Code (the “Code”),
all licenses and rights to licenses granted under or pursuant to this Agreement by Company to Merck are, and shall otherwise be
deemed to be, for purposes of Section 365(n) of the Code, licenses of rights to “intellectual property” as defined
under Section 101(35A) of the Code. The Parties agree that Merck, as a licensee of such rights under this Agreement, shall retain
and may fully exercise all of its rights and elections under the Code, and that upon commencement of a bankruptcy proceeding by
or against Company under the Code, Merck shall be entitled to a complete duplicate of or complete access to (as Merck deems appropriate),
any such intellectual property and all embodiments of such intellectual property. Such intellectual property and all embodiments
thereof shall be promptly delivered to Merck: (i) upon any such commencement of a bankruptcy proceeding upon written request therefore
by Merck, unless Company elects to continue to perform all of its obligations under this Agreement; or (ii) if not delivered under
(i) above, upon the rejection of this Agreement by or on behalf of Company upon written request therefore by Merck.

 

The foregoing provisions of Section
8.3.2(d) are without prejudice to any rights Merck may have arising under the Code or other applicable law.

 

		8.4	[***] 

 

		8.5	Effect of Expiration or Termination; Survival. Expiration or
termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination.
Any expiration or termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued
or accruing under this Agreement prior to expiration or termination, including without limitation the obligation to pay royalties
for Product(s) or Compound sold prior to such expiration or termination. The provisions of Article 4 shall survive the expiration
or termination of this Agreement and shall continue in effect for ten (10) years. In addition, the provisions of Article 1,
Article 3, Article 6, Article 7, Article 8, Article 9 and Sections 2.6, 2.8, 2.9, 2.11 and
5.2 - 5.8 shall survive any expiration or termination of this Agreement.

 

    	 	41	 

     

    

 

Article
9  MISCELLANEOUS

 

		9.1	Force Majeure. Neither Party shall be held liable to the other
Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under
this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected
Party, potentially including, but not limited to, embargoes, war, acts of war (whether war be declared or not), acts of terrorism,
insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts,
omissions or delays in acting by any governmental authority or the other Party. The affected Party shall notify the other Party
of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary
to cure such force majeure circumstances.

 

		9.2	Assignment/Change of Control. Except as provided in this Section
9.2, this Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or
transferred, by either Party without the consent of the other Party.

 

		9.2.1	Merck may, without consent of Company, assign this Agreement and its rights and obligations hereunder
in whole or in part to an Affiliate of Merck or in connection with a Change of Control.

 

		9.2.2	Company may assign this Agreement in its entirety to the successor party in connection with a Change
of Control. In the event that there is a Company Change of Control that is a Competing Pharma Change of Control, then Company shall
provide written notice to Merck at least thirty (30) days prior to the completion of such Change of Control, i.e., the closing
of the transaction that results in Change of Control, and Merck shall have the right, at Merck election at any time after such
Change of Control to implement some or all of the following revisions to this Agreement:

 

		(a)	Merck may limit its obligations to provide Company royalty related reports pursuant to Section
5.5 to reporting only Merck’s total royalty obligations; provided that, Merck will, if requested by Company, provide
royalty reports specified in such Section 5.5 to an independent certified public accounting firm for auditing in accordance
with Section 5.6.

 

		(b)	Merck shall have the right to require Company, including the Change of Control party, to adopt
reasonable procedures to be agreed upon in writing with Merck to prevent the disclosure of all Information of Merck and other information
with respect to the Research, Development, Manufacture and Commercialization of Compounds and Products (collectively “Sensitive
Information”) beyond Company personnel having access to and knowledge of Sensitive Information prior to the Change of
Control and to control the dissemination of Sensitive Information disclosed after the Change of Control. The purposes of such procedures
shall be to strictly limit such disclosures to only those personnel having a need to know Sensitive Information in order for Company
to perform its obligations under this Agreement and to prohibit the use of Sensitive Information for competitive reasons against
Merck and its Related Parties, and for Compounds or Products, including without limitation, the use of Sensitive Information for
the research, development or commercialization of competing products.

 

    	 	42	 

     

    

 

		9.2.3	In the event that there is a Company Change of Control: [***].

 

		9.2.4	Any attempted assignment not in accordance with this Section 9.2 shall be void. Any permitted
assignee shall assume all assigned obligations of its assignor under this Agreement.

 

		9.3	Use of Affiliates. Merck shall have the right to exercise its
rights and perform its obligations under this Agreement either itself or through any of its Affiliates.

 

		9.4	Severability. If any one or more of the provisions contained
in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining
provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s)
adversely affects the substantive rights of the Parties. The Parties shall in such an instance use reasonable efforts to replace
the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical,
implement the purposes of this Agreement.

 

    	 	43	 

     

    

 

		9.5	Notices. All notices which are required or permitted hereunder
shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered
or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by registered or certified mail,
postage prepaid, return receipt requested, addressed as follows:

 

	 	if to Company, to:	
        Cue Biopharma, Inc.

        675 West Street

        Cambridge, MA 02142

        Attention: Daniel Passeri, President and CEO

        Email: dpasseri@cuebio.com

	 	 	 
	 	and:	Mark R. Busch

    K&L Gates LLP

    214 North Tryon Street, 47th Floor

    Charlotte, NC 28202

    Phone: 704.331.7440

    Fax: 704.353.3694

    mark.busch@klgates.com
	 	 	 
	 	if to Merck, to:	
        Merck Sharp & Dohme Corp.

        One Merck Drive

        Whitehouse Station, NJ 08889-0100

        Attention: Office of Secretary

        Facsimile No.: (908) 735-1246

	 	 	 
	 	And	
        Merck Sharp & Dohme Corp.

        2000 Galloping Hill Road

        PO Box 539

        Mailstop K-1-4161

        Kenilworth, NJ 07033-1310

        Attention: Senior Vice President,
Business Development

 

or to such other address(es) as the
Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall
be deemed to have been given: (a) when delivered if personally delivered or sent by facsimile on a business day (or if delivered
or sent on a non-business day, then on the next business day); (b) on the business day after dispatch if sent by nationally-recognized
overnight courier; or (c) on the fifth (5th) business day following the date of mailing, if sent by mail. The Parties hereby agree
that, to the extent permitted by law, any notice provided in accordance with this Section 9.5 shall constitute due service
of process with respect to any legal proceeding between the Parties arising hereunder and that compliance with the Hague Convention
for the Service of Process, if otherwise applicable, shall not be required.

 

		9.6	Applicable Law. This Agreement shall be governed by and construed
in accordance with the laws of the State of New York without reference to any rules of conflict of laws or renvoi.

 

    	 	44	 

     

    

 

		9.7	Dispute Resolution.

 

		9.7.1	The Parties shall negotiate in good faith and use reasonable efforts to settle any dispute, controversy
or claim arising from or related to this Agreement or the breach thereof (a “Dispute”). Any Party shall give
the other Party written notice of any Dispute not resolved in the normal course of business. Within twenty (20) days from the date
of delivery of such notice, the receiving Party shall submit to the other Party a written response. The notice and response shall
include (a) a statement of that Party's position and a summary of arguments supporting that position, and (b) the name and title
of the executive who will represent that Party and of any other person who will accompany the executive. Within forty-five (45)
days from the date of delivery of the initial notice, the executives of both Parties shall meet at a mutually acceptable time and
place, and thereafter as often as they reasonably deem necessary, to attempt to resolve the Dispute. These executives shall have
the authority to settle the Dispute and shall be at a higher level of management than the persons with direct responsibility for
administration of this Agreement. All negotiations pursuant to this paragraph are confidential and shall be treated as compromise
and settlement negotiations for purposes of applicable rules of evidence.

 

		9.7.2	If the Parties do not fully settle following the procedure in Section 9.7.1, and a Party
wishes to pursue the matter, each dispute, controversy or claim arising from or related to this Agreement or the breach thereof
that is not an “Excluded Claim” shall be brought in the federal court for the Southern District of New York,
if federal jurisdiction is available, or, alternatively, in the state court in the borough of Manhattan, New York City, New York.
Each of the Parties hereby submits to the exclusive jurisdiction of such courts for the purpose of any such litigation; provided,
that a final judgment in any such litigation shall be conclusive and may be enforced in other jurisdictions by suit on the judgment
or in any other manner provided by law. Each party irrevocably and unconditionally agrees not to assert (a) any objection which
it may ever have to the laying of venue of any such litigation in such courts, (b) any claim that any such litigation brought in
any such court has been brought in an inconvenient forum, and (c) any claim that such court does not have jurisdiction with respect
to such litigation. Each party irrevocably
and unconditionally waives any right to a trial by jury and agrees that any of them may file a copy of this paragraph with any
court as written evidence of the knowing, voluntary and bargained-for agreement among the Parties irrevocably to waive its right
to trial by jury in any LITIGATION.

 

		9.7.3	As used in this Section 9.7, the term “Excluded
Claim” shall mean a dispute, controversy or claim that concerns (a) a decision by the Joint Steering Committee,
the Patent Committee, or Merck within the proper scope of the Committee’s authority pursuant to Section 2.4 or Section 2.5,
or an issue concerning the integrity of data submitted to a regulatory agency, neither of which shall be arbitrable or justiciable
in any forum; (b) the validity or infringement of a patent, trademark or copyright; or (c) any antitrust, anti-monopoly or competition
law or regulation, whether or not statutory. Any action concerning Excluded Claims identified in clauses (b) and (c) of this Paragraph
may be brought in any court having jurisdiction.

 

		9.8	Limitation of Liability. Notwithstanding anything to the contrary
contained herein, no party shall be liable to another party under any theory for any special, incidental, indirect, consequential
or other similar damages, or any punitive damages, whether arising directly or indirectly out of the transactions contemplated
by this Agreement. To be clear, neither party shall be entitled to recover for any lost profit or lost sale damages of any kind,
whether those claimed damages are direct or indirect.

 

    	 	45	 

     

    

 

		9.9	Entire Agreement; Amendments. This Agreement, together with the
Schedules and Exhibits hereto, contains the entire understanding of the Parties with respect to the subject matter hereof. Any
other express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, with respect
to the subject matter hereof are superseded by the terms of this Agreement. The Schedules and Exhibits to this Agreement are incorporated
herein by reference and shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof modified, only
by a written instrument duly executed by authorized representative(s) of both Parties hereto.

 

Notwithstanding anything to the
contrary in the foregoing, that certain confidentiality agreement between the Parties dated as of May 15, 2017, shall remain in
full force and effect with respect to the subject matter thereof and information disclosed thereunder.

 

		9.10	Headings. The captions to the several Articles, Sections and
subsections hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading the several
Articles and Sections hereof.

 

		9.11	Independent Contractors. It is expressly agreed that Company
and Merck shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership,
joint venture or agency. Neither Company nor Merck shall have the authority to make any statements, representations or commitments
of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party.

 

		9.12	Waiver. The waiver by either Party hereto of any right hereunder,
or of any failure of the other Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other
right hereunder or of any other breach by or failure of such other Party whether of a similar nature or otherwise.

 

		9.13	Waiver of Rule of Construction. Each Party has had the opportunity
to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction
that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply.

 

		9.14	Certain Conventions. Any reference in this Agreement to an Article,
Section, subsection, paragraph, clause, Schedule or Exhibit shall be deemed to be a reference to an Article, Section, subsection,
paragraph, clause, Schedule or Exhibit, of or to, as the case may be, this Agreement, unless otherwise indicated. Whenever this
Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. Unless the context of this
Agreement otherwise requires, (a) words of any gender include each other gender, (b) words such as “herein”, “hereof”,
and “hereunder” refer to this Agreement as a whole and not merely to the particular provision in which such words appear,
(c) words using the singular shall include the plural, and vice versa.

 

		9.15	Business Day Requirements. In the event that any notice or other
action or omission is required to be taken by a Party under this Agreement on a day that is not a business day (excluding notices
required under Section 3.6), then such notice or other action or omission shall be deemed to be required to be taken on
the next occurring business day. 

 

    	 	46	 

     

    

 

Counterparts.
This Agreement may be signed in any number of counterparts (including by facsimile or electronic
transmission), each of which shall be deemed an original, but all of which shall constitute one and the same instrument. After
facsimile or electronic transmission, the Parties agree to execute and exchange documents with original signatures.

 

[Remainder of
page intentionally left blank. Signature page follows.]

 

    	 	47	 

     

    

 

IN WITNESS WHEREOF, the Parties have executed this Agreement
as of the Effective Date.

 

	MERCK SHARP & DOHME CORP.	 	CUE BIOPHARMA, INC.
	 	 	 
	BY:	/s/ [***]	 	BY:	/s/ Daniel Passeri
	 	[***]	 	 	Daniel Passeri
	 	 	 	 	 
	TITLE: Senior Vice President and Global	 	TITLE: President and CEO
	Head of Business Development & LicensingExhibit 10.22

 

CUE BIOPHARMA, INC.

 

EXECUTIVE EMPLOYMENT AGREEMENT 

 

This Executive Employment
Agreement (“Agreement”), dated as of November 15, 2017 (the “Effective Date”), is made by
and between Cue Biopharma, Inc., a Delaware corporation (“Cue”) and Colin Sandercock (“Executive,”
and together with Cue, the “Parties”).

 

WHEREAS, Cue desires
to employ Executive, and Executive desires to be so employed, pursuant to the terms of this Agreement.

 

NOW, THEREFORE, in
consideration of the foregoing, of the mutual promises contained herein and of other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

 

		1.	POSITION AND DUTIES.

 

(a)          Cue
shall employ Executive as its Senior Vice President and General Counsel (“General Counsel”), beginning December
4, 2017. In his role as General Counsel, Executive shall have such duties and authority commensurate with the position of General
Counsel, and such other duties commensurate with the positions that may be assigned by the Board of Directors of Cue (the “Board”),
or the Chief Executive Officer of Cue (the “CEO”).

 

(b)          Executive
shall report directly to the CEO.

 

(c)          During
the Term (as defined below), Executive shall devote all of Executive’s business time, energy, judgment, knowledge and skill
and Executive’s best efforts to the performance of Executive’s duties with Cue, provided that the foregoing
shall not prevent Executive from (i) providing legal services to unrelated third-party clients as needed, (ii) participating in
charitable, civic, educational, professional, community or industry affairs or (iii) managing Executive’s passive personal
investments, so long as such activities of (i)-(iii) above are generally conducted outside of normal business hours or require
de minimis amounts of Executive’s time, unless otherwise approved by the Company, and in the aggregate do not interfere or
conflict with Executive’s duties hereunder or create a potential business or fiduciary conflict.

 

2.            TERM.
Subject to the remaining terms of this Section 2, this Agreement shall be for an initial term that begins on the
Effective Date and continues in effect through December 31, 2018 (the “Initial Term”) and, unless terminated
sooner as herein provided, shall continue on a year-to-year basis after the Initial Term (each year, a “Renewal Term,”
and each Renewal Term together with the Initial Term, the “Term”). If either Party elects not to renew this
Agreement, that Party must give a written notice of non-renewal to the other Party at least 60 days before the expiration of the
then-current Initial Term or Renewal Term. In the event that one Party provides the other with a notice of non-renewal pursuant
to this Section 2, no further automatic extensions shall occur and this Agreement shall terminate at the end of the
then-existing Initial Term or Renewal Term, as applicable. If Cue provides Executive with notice of non-renewal, then the compensation
provisions of Section 8(c) for Termination Without Cause shall be paid to Executive.

 

3.            BASE
SALARY. Cue shall pay Executive a base salary (“Base Salary”) at an annual rate of $275,000 during the Term,
in accordance with the regular payroll practices of Cue. The Base Salary shall be subject to annual review and upward adjustment
in accordance with the Company’s normal compensation practices.

 

     

     

    

 

4.           ANNUAL
BONUS. Each year during the Term, Executive shall be eligible to receive an annual incentive bonus (the “Annual Bonus”)
of up to 20% of the Base Salary, subject to achievement of key performance indicators for Cue, with the level of achievement determined
by the Compensation Committee of the Board or its delegate (the “Committee”) in its sole discretion. The Committee
shall establish such key performance indicators in its sole discretion and in consultation with Executive. The terms of the Annual
Bonus developed by the Committee shall govern any Annual Bonus that may be paid. Any Annual Bonus shall be paid in all events within
two and one-half months after the end of the year in which such Annual Bonus becomes earned, provided that no Annual Bonus
shall be considered earned until the Board makes all necessary determinations with respect to the Annual Bonus.

 

		5.	STOCK OPTIONS.

 

(a)          NUMBER
OF SHARES. Upon completion of a Financing (defined below), Executive shall be granted Options (as defined in the Cue Biopharma,
Inc. 2016 Omnibus Incentive Plan (the “Plan”)) to purchase 250,000 shares of Cue’s common stock (the “Common
Stock”) (the “Options”) pursuant to award agreements substantially in the forms previously provided
to Executive.

 

(b)          EXERCISE
PRICE; TERM. The exercise price per share of the Options shall be equal to the price at which shares of Common Stock are sold
in the Company’s initial public offering or other equity financing transaction, whichever occurs first (a “Financing
Transaction”). The Options shall have a term that expires seven years from the Grant Date.

 

(c)          PLAN
TERMS CONTROL. The Options shall be subject to the terms and conditions applicable to Options granted under the Plan, as described
in the Plan and the applicable Award Agreement (as defined in the Plan).

 

		6.	EMPLOYEE BENEFITS.

 

(a)          BENEFIT
PLANS. During the Term, Executive shall be entitled to participate in any employee benefit plans that Cue has adopted or may
adopt, maintains or contributes to for the benefit of its employees generally, subject to satisfying the applicable eligibility
requirements, except to the extent such plans are duplicative of the benefits otherwise provided to Executive hereunder. Executive’s
participation shall be subject to the terms of the applicable plan documents and generally applicable Cue policies. Notwithstanding
the foregoing, Cue may modify or terminate any employee benefit plan at any time.

 

(b)          VACATIONS.
During the Term, Executive shall be entitled to paid vacation time in accordance with Cue’s policy applicable to senior
management employees as in effect from time to time (the “Vacation Policy”); provided, however,
that Executive shall be entitled to no less than 20 days of paid vacation per calendar year, prorated for any partial years of
employment. Unused vacation time may not be carried forward from one calendar year to any subsequent calendar year, except to the
extent specifically permitted under the Vacation Policy.

 

(c)          BUSINESS
EXPENSES. Upon presentation of reasonable substantiation and documentation as Cue may require from time to time, Executive
shall be reimbursed in accordance with Cue’s expense reimbursement policy, for all reasonable out-of-pocket business expenses
incurred and paid by Executive during the Term and in connection with the performance of Executive’s duties hereunder. Executive
currently resides in McLean, Virginia and, as needed for Cue business and pursuant to the direction of the CEO, Executive shall
travel to Boston or elsewhere as directed by the CEO, and all reasonable expenses for travel, lodging and meals to and from Boston
or elsewhere as directed by the CEO, shall constitute reasonable out-of-pocket business expenses.

 

7.           TERMINATION.
Executive’s employment under this Agreement shall terminate on the first to occur of the following:

 

     

     

    

 

 

(a)          DISABILITY.
Upon 90 days’ prior written notice by Cue to Executive of termination due to Disability. “Disability”
shall mean Executive is unable to perform each of the essential duties of Executive’s position by reason of a medically determinable
physical or mental impairment that is potentially permanent in character or that can be expected to last for a continuous period
of not less than 12 months.

 

(b)          DEATH.
Automatically upon the death of Executive.

 

(c)          CAUSE.
Immediately upon written notice by Cue to Executive of a termination for Cause. “Cause” shall mean:

 

(i)          the
commission of any act by Executive constituting financial dishonesty against Cue or its Affiliates (which act would be chargeable
as a crime under applicable law);

 

(ii)         Executive’s
engaging in any other act of dishonesty, fraud, intentional misrepresentation, moral turpitude, illegality or harassment that would
(a) materially adversely affect the business or the reputation of Cue or any of its Affiliates with their respective current
or prospective customers, suppliers, lenders or other third parties with whom such entity does or might do business or (b) expose
Cue or any of its Affiliates to a risk of civil or criminal legal damages, liabilities or penalties;

 

(iii)        the
repeated failure by Executive to follow the lawful directives of the Board or CEO;

 

(iv)        any
willful, material misconduct, willful violation of Cue’s or its Affiliates’ policies, or willful and deliberate non-performance
of duty by Executive in connection with the business affairs of Cue or its Affiliates; or

 

(v)         Executive’s
material breach of a material term of this Agreement.

 

Executive shall be given written notice detailing
the specific Cause event and a period of 30 days following Executive’s receipt of such notice to cure such event in all material
respects (if susceptible to cure) to the reasonable satisfaction of the Board. All rights Executive has or may have under this
Agreement shall be suspended automatically during the pendency of any investigation by the Board or its designee, or during any
negotiations between the Board or its designee and Executive, regarding any actual or alleged act or omission by Executive of the
type described in this definition of Cause. For purposes of this Section 7(c), no action or failure to act on Executive’s
shall be considered “willful” unless done or omitted by Executive in bad faith and without reasonable belief that his
action was in the best interests of the Company.

 

(d)          GOOD
REASON. Upon written notice by Executive to Cue of a termination for Good Reason. “Good Reason” shall mean
the occurrence of any of the following events, without the consent of Executive, unless such events are fully corrected in all
material respects (if susceptible to cure) by Cue within 30 days following written notification by Executive to Cue of the occurrence
of one of the events:

 

(i)          a
diminution in Executive’s Base Salary or Annual Bonus opportunity;

 

(ii)         a
material diminution in Executive’s authority, responsibilities or duties set forth in Section 1 above, other
than temporarily while physically or mentally incapacitated, as required by applicable law; or

 

(iii)        a
material breach by Cue of a material term of this Agreement.

 

     

     

    

 

Executive shall provide Cue with a written
notice detailing the specific circumstances alleged to constitute Good Reason within 30 days after the occurrence of such circumstances,
and actually terminate employment within 30 days following the expiration of Cue’s 30-day cure period described above. Otherwise,
any claim of the occurrence of such circumstances as Good Reason shall be deemed irrevocably waived by Executive. For clarity,
a waiver of the occurrence of circumstances that constitute Good Reason shall not act as a waiver for any other occurrence of circumstances
that constitute Good Reason.

 

(e)          WITHOUT
CAUSE. Upon 120 days written notice by Cue to Executive of an involuntary termination without Cause (other than for death or
Disability).

 

(f)          VOLUNTARY
TERMINATION. Upon 60 days’ prior written notice by Executive to Cue of Executive’s voluntary termination of employment
without Good Reason (which Cue may, in its sole discretion, make effective earlier than any notice date).

 

		8.	CONSEQUENCES OF TERMINATION.

 

(a)          DEATH/DISABILITY.
In the event that Executive’s employment ends on account of Executive’s death or Disability, Executive or Executive’s
estate, as the case may be, shall be entitled to the following (with the amounts due under Sections 8(a)(i) through 8(a)(iv)
below to be paid within 60 days following termination of employment, or such earlier date as may be required by applicable law):

 

(i)          any
unpaid Base Salary through the date of termination;

 

(ii)         any
Annual Bonus for the year prior to the year in which such termination occurs that is earned but unpaid prior to the date of termination;

 

(iii)        reimbursement
for any unreimbursed business expenses incurred through the date of termination;

 

(iv)        any
accrued but unused vacation time in accordance with Cue policy, which shall be prorated for any year in which Executive’s
employment with Cue is terminated;

 

(v)         all
other payments, benefits or fringe benefits to which Executive shall be entitled under the terms of any applicable compensation
arrangement or benefit, equity or fringe benefit plan or program or grant (collectively, Sections 8(a)(i) through 8(a)(v)
hereof shall be hereafter referred to as the “Accrued Benefits”);

 

(vi)        an
Annual Bonus for the year in which such termination occurs, determined and payable pursuant to the terms and conditions of Section
4 above as though no such termination had occurred; and

 

(vii)        three
months of Base Salary, with such lump sum payable on the first payroll date of Cue that occurs more than 60 days after Executive’s
termination.

 

(b)          TERMINATION
FOR CAUSE OR WITHOUT GOOD REASON. If Executive’s employment is terminated (i) by Cue for Cause or (ii) by Executive without
Good Reason, Cue shall pay to Executive the Accrued Benefits (other than the Annual Bonus described in Section 8(a)(ii)
above).

 

(c)          TERMINATION
WITHOUT CAUSE OR FOR GOOD REASON. If Executive’s employment by Cue is terminated by Cue other than for Cause or Executive’s
death or Disability or by Executive for Good Reason, Cue shall pay or provide Executive the following:

 

(i)          the
Accrued Benefits; and

 

     

     

    

 

(ii)         subject
to Executive’s compliance with Section 9 below and Executive’s continued compliance with Section 10 below,
a lump sum cash severance payment in an amount equal to (A) the highest Annual Bonus payable for the year of termination, prorated
based on the number of days that Executive is employed in such year through the date of termination plus (B) six months of Base
Salary, with such lump sum payable on the first payroll date of Cue that occurs more than 60 days after Executive’s termination
plus (C) if Executive elects to continue medical, dental or other insurance under COBRA following such termination, the Company
shall pay the Executive for Executive’s COBRA premiums for such coverage for the six-month period after termination (collectively,
the “Severance Amount”).

 

Payments and benefits provided under this Section 8(c)
shall be in lieu of any termination or severance payments or benefits to which Executive may be eligible under any of the plans,
policies or programs of Cue or under the Worker Adjustment Retraining Notification Act of 1988, as amended, or any similar state
statute or regulation. Should Executive die prior to the payment of the Severance Amount, the Severance Amount shall be paid to
the heirs or estate of Executive in accordance with the schedule set forth herein.

 

(d)          OTHER
OBLIGATIONS. Upon any termination of Executive’s employment with Cue, Executive shall automatically be deemed to have
resigned from any and all other positions he then holds as an officer, director or fiduciary of Cue and any other entity that is
part of the same consolidated group as Cue or in which capacity Executive serves at the direction of or as a result of his position
with Cue; and Executive shall, within 10 days of such termination, take all actions as may be necessary under applicable law or
requested by Cue to effect any such resignations.

 

(e)          EXCLUSIVE
REMEDY. The amounts payable to Executive following termination of employment hereunder pursuant to Sections 8(a),
(b) and (c) above shall be in full and complete satisfaction of Executive’s rights under this Agreement and
any other claims that Executive may have in respect of Executive’s employment with Cue or any of its Affiliates, and Executive
acknowledges that such amounts are fair and reasonable, and are Executive’s sole and exclusive remedy, in lieu of all other
remedies at law or in equity, with respect to the termination of Executive’s employment hereunder or any breach of this Agreement.

 

(f)          NO
MITIGATION OR OFFSET. Executive shall not be required to seek or accept other employment or otherwise to mitigate damages as
a condition to the receipt of benefits pursuant to this Section 8, and amounts payable pursuant to this Section 8
shall not be offset or reduced by any amounts received by Executive from other sources.

 

(g)          NO
WAIVER OF ERISA-RELATED RIGHTS. Nothing in this Agreement shall be construed to be a waiver by Executive of any benefits accrued
for or due to Executive under any employee benefit plan (as such term is defined in the Employee Retirement Income Security Act
of 1974, as amended) maintained by Cue, if any, except that Executive shall not be entitled to any severance benefits pursuant
to any severance plan or program of Cue other than as provided herein.

 

(h)          CLAWBACK.
All awards, amounts or benefits received or outstanding under this Agreement shall not be subject to clawback, cancellation, recoupment,
rescission, payback, reduction or other similar action unless required by law.

 

9.            RELEASE.
Any and all amounts payable and benefits or additional rights provided pursuant to this Agreement upon termination beyond the
Accrued Benefits shall only be payable if Executive delivers to Cue and does not revoke a general release of claims in favor of
Cue in a form satisfactory to Cue. Such release shall be furnished to Executive within two business days after Executive’s
date of termination, and must be executed and delivered (and no longer subject to revocation, if applicable) within 30 days following
termination (or such longer period to the extent required by law).

 

     

     

    

 

		10.	RESTRICTIVE COVENANTS.

 

		(a)	Confidentiality.

 

(i)          Company
Information. At all times during the Term and thereafter, Executive shall hold in strictest confidence, and shall not
use, except in connection with the performance of Executive’s duties, and shall not disclose to any person or entity, any
Confidential Information of Cue. “Confidential Information” means any Cue proprietary or confidential information,
technical data, trade secrets or know-how, including research, product plans, products, services, customer lists and customers,
markets, software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, marketing, distribution
and sales methods and systems, sales and profit figures, finances and other business information disclosed to Executive by Cue,
either directly or indirectly in writing, orally or by drawings or inspection of documents or other tangible property. However,
Confidential Information does not include any of the foregoing items which has become publicly known and made generally available
through no wrongful act of Executive.

 

(ii)         Executive-Restricted
Information. During the Term, Executive shall not improperly use or disclose any proprietary or confidential information
or trade secrets of any person or entity with whom Executive has an agreement or duty to keep such information or secrets confidential.

 

(iii)        Third
Party Information. Executive recognizes that Cue has received and in the future will receive from third parties their
confidential or proprietary information subject to a duty on Cue’s part to maintain the confidentiality of such information
and to use it only for certain limited purposes. At all times during the Term and thereafter, Executive shall hold in strictest
confidence, and shall not use, except in connection with the performance of Executive’s duties, and shall not disclose to
any person or entity, such third party confidential or proprietary information, and shall not use it except as necessary in performing
Executive’s duties, consistent with Cue’s agreement with such third party.

 

		(b)	NONSOLICITATION; NONINTERFERENCE.

 

(i)          During
Executive’s employment with Cue and for a period of 24 months thereafter, Executive shall not, except in the furtherance
of Executive’s duties with Cue, directly or indirectly, individually or on behalf of any other person or entity, (i) solicit,
aid or induce any customer of Cue or its Affiliates with whom Executive had meaningful business contact to purchase goods or services
then sold by Cue or its Affiliates from another person or entity or assist or aid any other person or entity with whom Executive
had meaningful business contact in identifying or soliciting any such customer, or (ii) interfere, or aid or induce any other person
or entity with whom Executive had meaningful business contact in interfering, with the relationship between Cue or its Affiliates
and any of their respective vendors, customers, joint venturers, licensees or licensors. If a customer of Cue or its Affiliates
contacts Executive about legal representation, Executive shall be free to provide legal representation consistent with the Rules
of Professional Conduct of the applicable jurisdiction.

 

(ii)         During
Executive’s employment with Cue and for a period of 24 months thereafter, Executive shall not, except in the furtherance
of Executive’s duties with Cue, directly or indirectly, individually or on behalf of any other person or entity, solicit,
aid or induce any employee, consultant, representative or agent of Cue or its Affiliates (or any employee, consultant, representative
or agent who has left the employment or retention of Cue or its Affiliates less than one year prior to the date that Executive
solicits, aids or induces such person or entity (a “Covered Person”)) to any other person or entity unaffiliated
with Cue or hire or retain any such employee, consultant, representative or agent or any Covered Person, or take any action to
materially assist or aid any other person or entity in identifying, hiring or soliciting any such employee, consultant, representative
or agent or any Covered Person.

 

     

     

    

 

(c)          NONDISPARAGEMENT.
Executive shall not make negative comments or otherwise disparage Cue or any company or other trade or business that “controls,”
is “controlled by” or is “under common control with,” Cue within the meaning of Rule 405 of Regulation
C under the Securities Act, including any “subsidiary corporation” of Cue within the meaning of Section 424(f) of the
Internal Revenue Code of 1986 (“Affiliates”) or any of their officers, directors, managers, employees, consultants,
equityholders, agents or products. The foregoing shall not be violated by truthful statements (i) in response to legal process,
required governmental testimony or filings or administrative or arbitral proceedings (including depositions in connection with
such proceedings) or (ii) made in the course of Executive discharging his duties for Cue.

 

(d)          COOPERATION.
Upon the receipt of reasonable notice from Cue, while employed by Cue and thereafter, Executive shall respond and provide information
with regard to matters in which Executive has knowledge as a result of Executive’s employment with Cue, and shall provide
reasonable assistance to Cue, its Affiliates and their respective representatives in defense of any claims that may be made against
Cue or its Affiliates, and shall assist Cue and its Affiliates in the prosecution of any claims that may be made by Cue or its
Affiliates, to the extent that such claims may relate to the period of Executive’s employment with Cue (collectively, the
“Claims”). Executive shall promptly inform Cue if Executive becomes aware of any lawsuits involving Claims that
may be filed or threatened against Cue or its Affiliates. Executive also shall promptly inform Cue (to the extent that Executive
is legally permitted to do so) if Executive is asked to assist in any investigation of Cue or its Affiliates (or their actions)
or another party attempts to obtain information or documents from Executive (other than in connection with any litigation or other
proceeding in which Executive is a party-in-opposition) with respect to matters Executive believes in good faith to relate to any
investigation of Cue or its Affiliates, in each case, regardless of whether a lawsuit or other proceeding has then been filed against
Cue or its Affiliates with respect to such investigation, and shall not do so unless legally required. During the pendency of any
litigation or other proceeding involving Claims, Executive shall not communicate with anyone (other than Executive’s attorneys
and tax and/or financial advisors and except to the extent that Executive determines in good faith is necessary in connection with
the performance of Executive’s duties hereunder) with respect to the facts or subject matter of any pending or potential
litigation or regulatory or administrative proceeding involving Cue or any of its Affiliates without getting the prior written
consent of Cue. Upon presentation of appropriate documentation, Cue shall pay or reimburse Executive for all reasonable out-of-pocket
travel, duplicating or telephonic expenses incurred by Executive in accordance with Cue’s applicable policies in complying
with this Section 10(e), and Executive shall be compensated by Cue at a reasonable hourly rate for assistance given
after the end of the Term.

 

(e)          Ownership
of Information, Ideas, Concepts, Improvements, Discoveries and Inventions, and all Original Works of Authorship.

 

(i)          As
between the Parties, all information, ideas, concepts, improvements, discoveries and inventions, whether patentable or not, which
are conceived, made, developed or acquired by Executive or which are disclosed or made known to Executive, individually or in conjunction
with others, during the Term and which relate to Cue’s business, products or services (including all such information relating
to corporate opportunities, research, financial and sales data, pricing and trading terms, evaluations, opinions, interpretations,
acquisition prospects, the identity of clients or customers or their requirements, the identity of key contacts within the client
or customers’ organizations or within the organization of acquisition prospects, or marketing and merchandising techniques,
prospective names and marks) are and shall be the sole and exclusive property of Cue. Moreover, all drawings, memoranda, notes,
records, files, correspondence, manuals, models, specifications, computer programs, maps and all other writings or materials of
any type embodying any of such information, ideas, concepts, improvements, discoveries and inventions are and shall be the sole
and exclusive property of Cue.

 

     

     

    

 

(ii)         In
particular, Executive hereby specifically assigns and transfers to Cue all of Executive’s worldwide right, title and interest
in and to all such information, ideas, concepts, improvements, discoveries or inventions, and any United States or foreign applications
for patents, inventor’s certificates or other industrial rights that may be filed thereon, and applications for registration
of such names and marks. During the Term and thereafter, Executive shall assist Cue and its nominee at all times in the protection
of such information, ideas, concepts, improvements, discoveries or inventions, both in the United States and all foreign countries,
including the execution of all lawful oaths and all assignment documents requested by Cue or its nominee in connection with the
preparation, prosecution, issuance or enforcement of any applications for United States or foreign letters patent, and any application
for the registration of such names and marks.

 

(iii)        Moreover,
if during the Term, Executive creates any original work of authorship fixed in any tangible medium of expression which is the subject
matter of copyright (such as reports, videotapes, written presentations, computer programs, drawings, maps, architectural renditions,
models, manuals, brochures or the like) relating to Cue’s business, products or services, whether such work is created solely
by Executive or jointly with others, Cue shall be deemed the author of such work if the work is prepared by Executive in the scope
of Executive’s employment; or, if the work is not prepared by Executive within the scope of Executive’s employment
but is specially ordered by Cue as a contribution to a collective work, as a part of any written or audiovisual work, as a translation,
as a supplementary work, as a compilation or as an instructional text, then the work shall be considered to be work made for hire
and Cue shall be the author of the work. In the event such work is neither prepared by Executive within the scope of Executive’s
employment or is not a work specially ordered and deemed to be a work made for hire, then Executive shall assign, and by these
presents, does assign, to Cue all of Executive’s worldwide right, title and interest in and to such work and all rights of
copyright therein. Both during the Term and thereafter, Executive shall assist Cue and its nominee, at any time, in the protection
of Cue’s worldwide right, title and interest in and to the work and all rights of copyright therein, including the execution
of all formal assignment documents requested by Cue or its nominee and the execution of all lawful oaths and applications for registration
of copyright in the United States and foreign countries; provided, however, that Executive shall be compensated by
Cue at a reasonable hourly rate for assistance given after the end of the Term.

 

(iv)        Notwithstanding
the foregoing provisions of this Section 10(f), Cue hereby notifies Executive that the provisions of this Section 10(f)
shall not apply to any inventions for which no equipment, supplies, facility or trade secret information of Cue was used and which
were developed entirely on Executive’s own time, unless (A) the invention relates (1) to the business of Cue, or (2) to actual
or demonstrably anticipated research or development of Cue, or (B) the invention results from any work performed by Executive for
Cue.

 

(f)          RETURN
OF COMPANY PROPERTY. On the date of Executive’s termination of employment with Cue for any reason (or at any time prior
thereto at Cue’s request), Executive shall return all property belonging to Cue or its Affiliates (including any Cue or Affiliate-provided
laptops, computers, cell phones, wireless electronic mail devices or other equipment, or documents or property belonging to Cue
or an Affiliate).

 

(g)          EFFECT
OF EXECUTIVE BECOMING A BAD LEAVER. Notwithstanding any provision of this Agreement to the contrary, if (i) Executive breaches
any of the covenants set forth in this Agreement at any time during the period commencing on the Effective Date and ending 24 months
after Executive’s termination of employment with Cue for any reason and (ii) Executive fails to cure such breach within 30
days of the effective date of written notice of such breach given by Cue, then Executive shall be deemed a “Bad Leaver.”
If Executive is or becomes a Bad Leaver, then (i) any severance being paid to Executive pursuant to this Agreement or otherwise
shall immediately cease upon commencement of such action.

 

(h)          TOLLING.
If Executive violates any of the terms of the restrictive covenant obligations articulated herein, the balance of any such
obligation at issue will run from the first date on which Executive ceases to be in violation of such obligation.

 

     

     

    

 

11.         EQUITABLE
RELIEF AND OTHER REMEDIES. Executive acknowledges that Cue’s remedies at law for a breach or threatened breach of any
of the provisions of Section 10 above would be inadequate and in the event of such a breach or threatened breach, in
addition to any remedies at law, Cue, without posting any bond, shall be entitled to seek to obtain equitable relief in the form
of specific performance, a temporary restraining order, a temporary or permanent injunction or any other equitable remedy that
may then be available, without the necessity of showing actual monetary damages or the posting of a bond or other security.

 

12.         NO
ASSIGNMENTS. This Agreement is personal to each of the Parties. Except as provided in this Section 12, neither
Party may assign or delegate any rights or obligations hereunder without first obtaining the written consent of the other Party.
Cue may assign this Agreement to any of its Affiliates or to any successor to all or substantially all of the business and/or assets
of Cue, provided that Cue shall require such Affiliate or successor to expressly assume and agree to perform this Agreement
in the same manner and to the same extent that Cue would be required to perform it if no such succession had taken place. As used
in this Agreement, “Cue” shall mean Cue and any Affiliate or successor to its business and/or assets that assumes and
agrees to perform the duties and obligations of Cue under this Agreement by operation of law or otherwise.

 

13.         NOTICE.
Any notice that either Party may be required or permitted to give to the other shall be in writing and may be delivered personally,
by electronic mail or via a postal service, postage prepaid, to such electronic mail or postal address and directed to such person
as Cue may notify Executive from time to time; and to Executive at his electronic mail or postal address as shown on the records
of Cue from time to time, or at such other electronic mail or postal address as Executive, by notice to Cue, may designate in writing
from time to time.

 

14.         SECTION
HEADINGS; INCONSISTENCY. The section headings used in this Agreement are included solely for convenience and shall not affect,
or be used in connection with, the interpretation of this Agreement. In the event of any inconsistency between the terms of this
Agreement and any form, award, plan or policy of Cue, the terms of this Agreement shall govern and control.

 

15.         SEVERABILITY.
Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under
applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any
applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision
of this Agreement or any action in any other jurisdiction, but this Agreement shall be reformed, construed and enforced in such
jurisdiction.

 

16.         COUNTERPARTS.
This Agreement may be executed in several counterparts, each of which shall be deemed to be an original but all of which together
shall constitute one and the same instrument.

 

17.         Applicable
Law; Choice of Venue and Consent to Jurisdiction; Service of Process; waiver of jury trial.

 

(a)          All
questions concerning the construction, validity and interpretation of this Agreement and the performance of the obligations imposed
by this Agreement shall be governed by the internal laws of the State of Delaware applicable to agreements made and wholly to be
performed in such state without regard to conflicts of law provisions of any jurisdiction.

 

(b)          For
purposes of resolving any dispute that arises directly or indirectly from the relationship of the Parties evidenced by this Agreement,
the Parties hereby submit to and consent to the exclusive jurisdiction of the Commonwealth of Massachusetts and further agree that
any related litigation shall be conducted solely in the courts of Middlesex County, Massachusetts or the federal courts for the
United States for the District of Massachusetts, where this Agreement is made and/or to be performed, and no other courts.

 

(c)          Each
Party may be served with process in any manner permitted under State of Delaware law, or by United States registered or certified
mail, return receipt requested.

 

     

     

    

 

(d)          BY
EXECUTION OF THIS AGREEMENT, THE PARTIES ARE WAIVING ANY RIGHT TO TRIAL BY JURY IN CONNECTION WITH ANY SUIT, ACTION OR PROCEEDING
ARISING OUT OF OR BASED ON THIS AGREEMENT.

 

18.          MISCELLANEOUS.
No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed
to in writing and signed by Executive and such officer or director as may be designated by Cue. No waiver by either Party at any
time of any breach by the other Party of, or compliance with, any condition or provision of this Agreement to be performed by such
other Party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent
time. This Agreement together with all exhibits hereto sets forth the entire agreement of the Parties in respect of the subject
matter contained herein and supersedes any and all prior agreements or understandings between Executive and Cue or its Affiliates
with respect to the subject matter hereof. No agreements or representations, oral or otherwise, express or implied, with respect
to the subject matter hereof, have been made by either Party that are not expressly set forth in this Agreement.

 

19.          REPRESENTATIONS.
Executive represents and warrants to Cue that (a) Executive has the legal right to enter into this Agreement and to perform
all of the obligations on Executive’s part to be performed hereunder in accordance with its terms, and (b) Executive is not
a party to any agreement or understanding, written or oral, and is not subject to any restriction, which, in either case, could
prevent Executive from entering into this Agreement or performing all of Executive’s duties and obligations hereunder.

 

20.          TAX
MATTERS.

 

(a)          WITHHOLDING.
Any and all amounts payable under this Agreement or otherwise shall be subject to, and Cue may withhold from such amounts,
any federal, state, local or other taxes as may be required to be withheld pursuant to any applicable law or regulation.

 

(b)          SECTION
409A COMPLIANCE.

 

(i)          The
intent of the Parties is that payments and benefits under this Agreement be exempt from (to the extent possible) Section 409A (“Section
409A”) of the Internal Revenue Code of 1986 and the regulations and guidance promulgated thereunder, as amended (collectively,
the “Code”) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in
compliance therewith. To the extent that any provision hereof is modified in order to comply with Section 409A, such modification
shall be made in good faith and shall, to the maximum extent reasonably possible, maintain the original intent and economic benefit
to the Parties of the applicable provision without violating the provisions of Section 409A. In no event shall Cue be liable for
any additional tax, interest or penalty that may be imposed on Executive by Section 409A or damages for failing to comply with
Section 409A.

 

(ii)         A
termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the
payment of any amounts or benefits that constitute “nonqualified deferred compensation” under Section 409A upon or
following a termination of employment unless such termination is also a “separation from service” within the meaning
of Section 409A and, for purposes of any such provision of this Agreement, references to a “termination,” “termination
of employment” or like terms shall mean “separation from service.” Notwithstanding anything to the contrary in
this Agreement, if Executive is deemed on the date of termination to be a “specified employee” under Section 409A,
then with regard to any payment or the provision of any benefit that is considered “nonqualified deferred compensation”
under Section 409A payable on account of a “separation from service,” such payment or benefit shall not be made or
provided until the earlier of (A) the expiration of the six-month period measured from the date of such “separation from
service” of Executive, and (B) the date of Executive’s death, to the extent required under Section 409A. Upon the expiration
of the foregoing delay period, all payments and benefits delayed pursuant to this Section 20(b)(ii) (whether they would
have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed to Executive
in a lump sum on the first business day following the six-month period, and any remaining payments and benefits due under this
Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein.

 

     

     

    

 

(iii)        To
the extent that reimbursements or other in-kind benefits under this Agreement constitute “nonqualified deferred compensation”
for purposes of Section 409A, (A) all expenses or other reimbursements hereunder shall be made on or prior to the last day of the
taxable year following the taxable year in which such expenses were incurred by Executive, (B) any right to reimbursement or in-kind
benefits shall not be subject to liquidation or exchange for another benefit and (C) no such reimbursement, expenses eligible for
reimbursement or in-kind benefits provided in any taxable year shall in any way affect the expenses eligible for reimbursement,
or in-kind benefits to be provided, in any other taxable year.

 

(iv)        For
purposes of Section 409A, Executive’s right to receive any installment payments pursuant to this Agreement shall be treated
as a right to receive a series of separate and distinct payments. Whenever a payment under this Agreement specifies a payment period
with reference to a number of days, the actual date of payment within the specified period shall be at the sole discretion of the
Board.

 

(v)         Notwithstanding
any other provision of this Agreement to the contrary, in no event shall any payment under this Agreement that constitutes “nonqualified
deferred compensation” for purposes of Section 409A be subject to offset by any other amount unless otherwise permitted by
Section 409A.

 

(c)          Modification
of Payments. In the event it shall be determined that any payment, right or distribution by Cue or any other person
or entity to or for the benefit of Executive pursuant to the terms of this Agreement or otherwise, in connection with, or arising
out of, Executive’s employment with Cue or a change in ownership or effective control of Cue or a substantial portion of
its assets (a “Payment”) is a “parachute payment” within the meaning of Code Section 280G on account
of the aggregate value of the Payments due to Executive being equal to or greater than three times the “base amount,”
as defined in Code Section 280G (the “Parachute Threshold”), so that Executive would be subject to the excise
tax imposed by Code Section 4999 (the “Excise Tax”) and the net after-tax benefit that Executive would receive
by reducing the Payments to the Parachute Threshold is greater than the net after-tax benefit Executive would receive if the full
amount of the Payments were paid to Executive, then the Payments payable to Executive shall be reduced (but not below zero) so
that the Payments due to Executive do not exceed the amount of the Parachute Threshold, reducing first any non-cash Payments.

 

By
signing this Agreement Below, Executive acknowledges that Executive:

 

		(1)	has read and
understood the entire Agreement;

 

		(2)	has had the
opportunity to ask questions and consult counsel or other advisors about the agreement’s terms; and

 

		(3)	agrees to be
bound by the agreement.

 

     

     

    

 

In
witness whereof, Cue has caused this Agreement to be executed in its name and on its behalf, and Executive acknowledges
understanding and acceptance of, and agrees to, the terms of this Agreement, all as of the Effective Date.

 

	CUE BIOPHARMA, INC.	 	COLIN SANDERCOCK
	 	 	 
	/s/ Daniel R. Passeri	 	/s/ Colin Sandercock
	 	 	 	 
	Print Name: 	Daniel R. Passeri	 	 
	 	 	 	 
	Title:	Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}]]